

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

5,500

Open access books available

135,000

International authors and editors

165M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma

Li-Jun Xue¹, Quan-Sheng Su¹, Xiao-Bei Mao¹, Qing Lin¹, Xiao-Bei Liu¹,
Chang Liu², Yong Lin¹, Ji-Hong Yang¹, Hong-Ju Yu¹ and Xiao-Yuan Chu¹

¹Departments of Oncology and

²Gastroenterology, Jinling Hospital, Nanjing University School of Medicine, 305 East
Zhong-shan Road, Nanjing, Jiangsu Province,
China

1. Introduction

Gastric carcinoma (GC) remains one of the most malignant tumors either in morbidity or mortality rates around the world (IARC, 2002). Development of GC is influenced by multiple factors including genetic, biological, social, and psychological ones, etc., however, the function mechanisms of which are too sophisticated and still under explorations (Matysiak-Budnik & Mégraud, 2006). Similar to other malignant tumors, GC leads to death mainly due to system or organ failure because of cancer advancement and metastasis. Chemotherapy-based regimens combined with radiological and immunomodulating therapies are fundamental but unsatisfactory because most GC patients are in advanced stage when diagnosed, although radical operation throws those at early stage a light of prolonged survival and even clinical cure (Quiros & Bui, 2009). As for prophylaxis, many reports have mentioned the protective role of eradication of *Helicobacter pylori*, which has been identified as a definite carcinogen for GC, but few evidences proved a successful *H. pylori* vaccine showing effects on GC prevention, just as Hepatitis B virus vaccine on prevention of primary hepatocellular carcinoma (IARC, 1994; Murakami et al., 2005; Cai et al., 2005; Di Bisceglie 2009).

H. pylori, a stomach colonizing spiral gram-negative bacterium, interacts with the host in a multiplicity of ways during its adhesion, colonization, invasion, and induction of inflammatory and immune responses (Peek 2005). The great majority of researchers link *H. pylori* infection with development or even recurrence of GC according to some clinical trials, meta-analyses, and *in vitro* experiments (Wong et al., 2004; Fukase et al., 2008). However, a few recent studies have disclosed the other side of the coin, in which positive *H. pylori* status appears to be associated with better outlook in GC patients (Meimarakis et al., 2006; Marrelli et al., 2009). Therefore, *H. pylori* probably factually play a bi-directional role in GC just like a double-edged sword. To learn about both edges of *H. pylori* infection will provides us with new sights in vaccine design, prevention, and even therapy of GC.

Herein, we try to re-elucidate the relationship between *H. pylori* and GC from novel angles, in which GC consists of *H. pylori*-related (Hp-GC) and non-*H. pylori*-related (nHp-GC) ones,

and in which roles of the infection are divided into two parts including harmful and beneficial ones.

2. *H. pylori* virulence factors

H. pylori infection usually initiates from bacterial invasion, colonization, and expression and translocation of virulence factors, and persists through induction and maintenance of complex responses at certain levels in the host (Peek 2005). Herein, virulence factors extensively mean pathogenic components and contain those contributing to bacterial survival within the host, which are ever called as maintenance factors sometimes. According to the complete genome published and continuously updated since 1997, *H. pylori* (26695 strain) is of about 1.67 Mb in length with 1576 protein-coding genes, many of which encode virulent products associated with *H. pylori* pathogenesis (Tomb et al., 1997).

The cytotoxin-associated gene (*cag*) pathogenicity island (PAI), one of most well known virulence components, is of about 35 Kb with 26 open reading frames and is present in about 60% *H. pylori* strains in Europe and United States (Tomb et al., 1997; Peek 2005). Among all *Cag* PAI products, the *CagA* (*Cag26*) has been identified with relatively clear functions in development of GC (Huang et al., 2003). The involved carcinogenic mechanisms of *CagA* mainly include activation of certain signalling pathways such as Ras, SHP2, ERK, MAPK and JAK/STAT3, activation of C-terminal Src kinase and inhibition of Src activity, enhancement of epithelial gene transcription, disruption of cellular polarity, and morphological changes and final transformation of gastric epithelial cells (GECs) (Mimuro et al., 2002; Higashi et al., 2002; Selbach et al., 2002; Bagnoli et al., 2005; Lee et al., 2010).

Vacuolating toxin (*vacA*) of about 3.9 Kb is an independent key virulence determinant for *H. pylori* pathogenesis (Tomb et al., 1997). Around 60% of *H. pylori* strains produce detectable amounts of *VacA* *in vitro*, although this gene is present in all strains (Konturek et al., 2009). Cytotoxic activity of *VacA* varies considerably in different strains due to various gene subtypes based on sequence diversities in the N-terminal (allele types *s1a*, *s1b*, *s1c*, or *s2*) and middle regions (allele types *m1* or *m2*) (Atherton et al., 1995; Peek 2005). It has been demonstrated that infection with *vacA* *s1* and *m1* strains are associated with an increased risk of GC (Gerhard et al., 1999). *VacA* plays a role in carcinogenesis probably through inducing vacuolation and cellular detachment, permeabilizing epithelial cells, promoting apoptosis, and suppressing T-cell proliferation and activation (Peek 2005).

Outer membrane proteins (OMP) represent a large family of adhesins and participate in *H. pylori* infection mainly by mediating bacterial adherence and colonization in gastric mucosa (Odenbreit 2005). As one of OMP members, blood-group antigen-binding adhesin (*BabA*) can bind the blood-group antigen Lewis b on host epithelial cell membranes, and those strains possessing the encoding gene *babA2* are associated with high risk of GC (Oliveira et al., 2003; Konturek et al., 2009). Lipopolysaccharide (LPS), another cell wall component, can disrupt stomach mucosa and involve in the organism survival and persistence of *H. pylori* infection (Grebowska et al., 2008). Moreover, the LPS O-antigen mimics human Lewis x and Lewis y blood-group antigens, which also mediate bacterial adhesion and colonization and alternatively cause immune cross-reactivity (Moran 1996; Appelmelk et al., 2001).

There are still many other important virulence factors related with *H. pylori* infection and even carcinogenesis. Urease, an approximately 560-kDa hexameric enzyme consisting of 30-kDa *UreA* and 64-kDa *UreB* subunits, is produced abundantly by all *H. pylori* isolates (Turbett et al., 1992). Urease is independently essential for colonization and persistent

survival of the germ because it crucially contributes to local pH homeostasis within the stomach lumen (Stingl et al., 2002; Mollenhauer-Rektorschek et al., 2002). The induced by contact with epithelium factor Antigen (IceA), with two major allelic sequence variants of IceA1 and IceA2, is an independent strain-specific *H. pylori* locus significantly associated with distal GC (Kidd et al., 2001). IceA1 leads to relatively severer gastric inflammation and tissue damage following production induced by bacterial contact with GECs, which exists in 72% of the *H. pylori* isolates in a Chinese population (Sheu et al., 2002). Flagella are bacterial motile structures with two types of filaments, that are encoded by *flaA* and *flaB* genes and functionally regulated by *flgE* and *flbA* genes (Dunn et al., 1997). Normal expression and interaction of these virulence factors are required for bacterial motility or colonization during *H. pylori* infection.

Notably, *H. pylori* plays pathogenic or carcinogenic roles as an integrity, although its multiple virulence components have their own special contributions at various infection stages. The co-interactions among the virulence factors are likewise important for pathogenesis but may be so complex or always ignored and need further explorations. In addition, cross-interactions between *H. pylori* and the host are very vital for infection or carcinogenesis, which mainly contain inflammatory and immune responses, and genetic or phenotypic alterations (McNamara & El-Omar, 2008).

3. Inflammatory responses

H. pylori infection is firstly characterized by acute or chronic activation of inflammatory cells and release of multiple cytokines including pro-inflammatory and inflammatory ones (Peek 2005). The spectrum and relative levels of cytokines, to a certain extent, reflect the intensity of the host response to infection, which may result in different outcomes including gastric mucosal inflammation, injury, ulcer, and even cancer.

Cytokines such as tumor necrosis factor α (TNF- α), interleukin-1 β (IL-1 β) / IL-1 receptor antagonist (IL-1RN), IL-6, IL-8 and IL-10 are always significantly up-regulated in stomach mucosa, gastric fluids and the sera of *H. pylori*-infected patients and play vital functions in gastritis, metaplasia, dysplasia and carcinogenesis (McNamara & El-Omar, 2008). TNF- α and IL-1 are the most relevant factors consistently confirmed in animal models and various populations. TNF- α can markedly potentiate apoptosis, activate signalling pathways, influence mucosal inflammation and stimulate gastric acid secretion (Ierardi et al., 2003). Moreover, *H. pylori* causes sensitization of GECs for TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis, besides direct induction of apoptosis and inhibition of DNA synthesis (Tsai & Hsu, 2010). The *H. pylori* infection strengthens IL-1 functions in the carcinogenic process through complex pathways. IL-1 β and IL-1RN as key pro-inflammatory genotypes of IL-1, which is a powerful gastric acid suppressor, can increase the risk of atrophic gastritis (AG) and both intestinal and diffuse types of non-cardia GC (Starzyńska et al., 2006; Rad et al., 2004). IL-1 β with significantly higher level in neoplasm than in normal mucosa, involves in the carcinogenesis by stimulating hyper-proliferation in GECs via tyrosine kinase signalling (Beales 2002). *H. pylori*-induced gastritis is possibly driven in an IL-6-dependent fashion (Jackson et al., 2006). IL-6 participates in activation of the STAT3 signalling pathway by the translocated CagA in host cells, which may play a role in gastric carcinogenesis (Bronte-Tinkew et al., 2009). IL-6 level in the serum is related with GC status and its level in the tumor correlates significantly with lymphatic invasion and the depth of invasion (Kai et al., 2005). As for IL-8, its level in cancer tissues is more than double

fold in advanced GC than that in early GC irrespective of *H. pylori* status (Yamaoka et al., 2001). IL-8 modulates gastric acid secretion, promotes the proliferation, enhances the FasL-induced apoptosis, and mutually and dependently activates NF- κ B (Konturek et al., 2002; Varro et al., 2004; Guo et al., 2006). Moreover, IL-8 as a potent leukocyte chemoattractant, contributes to mucosal tissue injury and induces the upregulation and phosphorylation of EGFR and subsequent signalling events, which plays an fundamental role in carcinogenic mechanisms (Kassai et al., 1999; Beswick & Reyes, 2008). IL-10 inhibits the FasL-induced apoptosis in GECs though without significant effect on the transcription of Fas (Guo et al., 2006). IL-11 activates the STAT3 like IL-6 and concomitantly increases proliferation of GECs (Jackson et al., 2007).

Some other molecules including cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), nitric oxide (NO), inducible NO synthase (iNOS), monocyte chemoattractant protein 1 (MCP1), and hepatocyte growth factor (HGF) and c-MET also relate to GC-associated inflammatory responses (Zhuang X et al., 2001; Futagami et al., 2008; Snider & Cardelli, 2009; Cho et al., 2010). COX-2 as a key mediator in inflammation and cancer formation, together with PGE2, one of its major products, are remarkably up-regulated in *H. pylori*-related gastritis, GC, and precancerous lesions including atrophy, intestinal metaplasia (IM) and dysplasia of the stomach (Dong et al., 2009; Walduck et al., 2009; Zhang et al., 2009). COX-2 can be induced by gastrin, growth factors, inflammatory cytokines and reactive oxygen species in GECs (Seo et al., 2007). The overexpression of COX-2 may continue to exist in metaplastic or dysplastic mucosa even after successful *H. pylori* eradication, which increases the risk for carcinogenesis and indicates that COX-2 has a crucial role in not only Hp-GC but also nHp-GC (Tsuji et al., 2006). COX-2 overexpression is even thought as a biomarker of intestinal type and earlier stage of GC and an independent prognostic factor for worse survival (Park et al., 2009). COX-2 induces carcinogenesis mainly by inhibiting apoptosis, increasing proliferation and enhancing angiogenesis through multiple pathways including Wnt signalling, p38MAPK / ATF-2 pathway, TLR2 / TLR9 and c-Src-dependent NF- κ B activation, MMP-9 and VEGF activation, proteinase-activated receptor-2 signalling, PPAR γ inhibition, and so on (Leung et al., 2003; Chang et al., 2004 & 2005; Huang et al., 2006; Li et al., 2009; Zhang et al., 2009;). PGE2, a downstream mediator with central roles in the mentioned COX-2 pathways, plays important functions in both inflammation and carcinogenesis. PGE2 participates in IL-8 production in GECs, facilitates *H. pylori* colonization and persistent infection, and suppresses the immune functions of CD4 (+) T-helper 1 cells by silencing IL-2 gene transcription, which may help accelerate the tumor formation (Takehara et al., 2006; Toller et al., 2010).

During chronic *H. pylori* infection, there are still excessive amounts of reactive oxygen and nitrogen species containing NO and iNOS, which play crucial roles in the stepwise process of GC (Son et al., 2001; Tiwari et al., 2010). NO as an important endogenous carcinogenic factor, correlates with gastric hypoacidity, inhibits p53 expression, increases genetic and epigenetic changes by mediating mutation or DNA methylation, and perturbs the balance between apoptosis and proliferation in GECs (McGee & Mobley, 2000; Lamarque et al., 2003; Shiotani et al., 2004; Chen et al., 2006; Katayama et al., 2009;). Being one of independent prognostic factors, the iNOS overexpression is induced by *H. pylori* infection with involvements of TNF- α , Ras, AP-1, c-Fos and c-Jun, and related to apoptosis, angiogenesis, tumor progression, and poor survival in GC especially of the intestinal type (Tatemichi et al., 1998; Rieder et al., 2003; Chen et al., 2006; Cho et al., 2010). MCP-1 is significantly higher

at mRNA level in poorly differentiated GC, which has effect on COX-2 expression and subsequent PGE2 and VEGF production (Futagami et al., 2008). HGF is more frequently detected in GC tissue than in normal mucosa and shows a concentration-dependent increase under the stimulation of gastrin (Konturek et al., 2001 & 2003). Being the receptor of HGF, c-Met is activated by *H. pylori*, involved in malignant transformation of gastric mucosa and invasive growth of tumor cells, and strongly implicated in late-stage cancer progression and worse prognosis (Zhuang X et al., 2001; Churin et al., 2003; Snider & Cardelli, 2009). In addition, *H. pylori*-mediated GEC invasion depends on c-Met activation, besides on increased activities of MMP-2 and MMP-9 (Oliveira et al., 2006). The c-Met interacts with CagA and suppresses the phosphatidylinositol 3-kinase/Akt pathway, which then leads to β -catenin activation and NF- κ B signalling (Suzuki et al., 2009).

4. Immune responses

Another critical aspect of interactions between *H. pylori* and the host are immune responses, which consist of special and unspecialized ones. In fact, immune and inflammatory responses overlap each other especially in roles of many cytokines mentioned above during the infection and carcinogenesis. Herein we mainly focus on important alterations in antibody responses, status of immune cells, balance of cytokines, autoimmune reactions and immune tolerance.

4.1 Antibody responses

A significantly higher seroprevalence has been found in *H. pylori*-infected patients with gastritis, duodenal ulcer, or GC (Przyklenk et al., 1990). Some scientists have concluded that higher *H. pylori* seroprevalence is present in GC patients at early stages of tumor development compared those at advanced stages, whereas others have not (Lin et al., 1993; Klaamas et al., 1996; Komoto et al., 1998). Seropositivity of anti-*H. pylori* IgG is highly prevalent with 76% at 0-4 years and 99% by $>$ or $=$ 18 years of age in a rural population of Africa, where the immunological response is Th2-dominant, which may partly explain the lower risk of Hp-GC (Mbulaiteye et al., 2006). The immune serum-treated *H. pylori* cannot be eliminated *in vitro* by primary human macrophages, although serum enhances the bacteria uptake (Keep et al., 2010). Antibodies are not only dispensable for protection, but they impair both the elimination of bacteria and the development of gastritis. This effect appears to be IgA-dependent and is not a function of specific IgM or IgG antibodies (Akhiani 2005). The major antibodies responsive to *H. pylori* include IgA and IgG. GC patients elicit different anti-*H. pylori* IgG and IgA responses than the patients with atrophic and superficial gastritis (Manojlovic et al., 2008). IgA>IgG ratio and lower IgG is significantly more frequent in patients with GC and gastric lymphoma than those with gastritis and duodenal ulcer. Correspondingly, higher IgG and IgA levels are often observed in patients with duodenal ulcer or non-atrophic gastritis (Manojlovic et al., 2004 & 2008). As for subclass of IgG response, the IgG1 is lower in GC and AG patients than in gastritis ones; IgG2 is lower for patients with GC localized in the corpus. The IgG1 response in GC patients is correlated with *H. pylori* CagA status (Vorobjova et al., 2006). CagA-positive *H. pylori* strains also seem to markedly frequently induce an IgA response than CagA-negative strains. The presence of serum IgA antibodies likely indicates more severe late outcome of *H. pylori* infection (Rautelin et al., 2000). Anti-CagA antibodies are always higher in GC and AG compared with non-atrophic gastritis. As reported, Hp-GC patients are of 2-3 folds higher in CagA

seropositivity than age-matched *H. pylori*-positive non-GC controls. In addition, anti-CagA antibodies are significantly more prevalent among individuals with elevated titres of *H. pylori*-related IgA than in those only with IgG, with the exception of a small subgroup who later develop GC (Rautelin et al., 2000).

Heat shock protein (HSP) 60 may be associated with *H. pylori*-related gastritis and gastric carcinogenesis. The positivity rate for anti-HSP60 antibody is markedly higher not only in *H. pylori*-positive patients than in *H. pylori*-negative ones, but also in GC patients, especially of the diffuse type, than in *H. pylori*-positive non-GC patients (Tanaka et al., 2009). The isocitrate dehydrogenase (ICD) of *H. pylori*, as an antigen interacting with the host immune system subsequent to a possible autolytic release, significantly elicits humoral immune response and reveals high serum antibody titers in patients with gastritis and ulcer (Hussain et al., 2008). In addition, the *H. pylori*-induced inflammation leads to aberrant glycosylation and demasking of core peptide epitope of mucin 1 (MUC1), which could enhance the host immune responses (Klaamas et al., 2007). IgG immune response to tumor-associated MUC1 is up-regulated among *H. pylori*-infected individuals and related with a higher degree of inflammation in gastric mucosa. The level of anti-MUC1 IgG is positively correlated with that of anti-*H. pylori* IgG in both blood donors and patients with benign diseases, whereas the anti-MUC1 IgM level is not (Klaamas et al., 2007). Moreover, the anti-MUC1 IgG level is notably higher in GC patients than in blood donors, irrespective of *H. pylori* status or cancer stage. In some individuals, the *H. pylori* infection may stimulate specific response to tumor-associated MUC1 peptide thus modulating tumor immunity (Klaamas et al., 2007).

4.2 Status of immune cells

The infiltration of T, B and macrophage cells always increases at the gastric site of infection with *H. pylori*. The status of T cells and macrophage are closely associated with local and system protective immune responses including native and acquired ones, whereas B cells mainly play more roles in antibody responses and deregulated and exhaustive *H. pylori*-induced T cell-dependent B-cell activation even supports the onset of stomach B-cell lymphoma (D'Elis et al., 2005).

The tumor-infiltrating lymphocytes (TIL) from primary tumors have been isolated and analyzed to characterize the anti-tumor immune responses in GC patients (van den Engel et al., 2006). The CD3 (+) T cell population contains 50% CD4 (+) and 39% CD8 (+) cells. The number of CD19 (+) B cells significantly increases but that of CD3 (+) T cells significantly decreases in intestinal compared to diffuse type of GC. Most of T cell cultures derived from isolated TILs in Hp-GC patients secrete both IFN- γ and IL-5 when stimulated with autologous tumor cells (van den Engel et al., 2006).

There is a significant tendency of Th1/Th2 polarization in patients with *H. pylori* infection, especially of those with CagA positive strains (Wang et al., 2007). Protection against *H. pylori* infection including inhibition of bacterial colonization, is mainly mediated by CD4 (+) Th1 cell-mediated immunity (Inoue et al., 2009). Th1-mediated cellular immunity is associated with earlier stages of GC, while Th2-mediated humoral immunity dominates the advanced stages and is negatively associated with an abundance of regulatory T-cells (Treg) (Wang et al., 2007).

Treg cells of positive CD4, CD25 and Foxp3, suppress the host immune response to *H. pylori* infection and have been identified as the major regulatory factor of adaptive immune responses (Kandulski et al., 2010). Vaccine-induced protection against *H. pylori* correlates

with an augmented local recall response in the gastric mucosa, reduced amount of Treg, and increased proportions of neutrophils and CD4 (+) T cells (Becher et al., 2010). The CD4 (+) T cells isolated from stomachs of vaccinated mice can proliferate *in vitro* in response to *H. pylori* antigen, and secrete Th1 cytokines, particularly IFN- γ . The efficiency of these vaccines relates to the alteration of gastric immune responses, from a homogeneous Th1 response to a mixed Th1 and Th2 response (Ernst et al., 2001). The functions of Treg cells are either mediated by direct cell-cell contact or by secretions of the immune-modulating TGF- β 1 and IL-10 cytokines (Kandulski et al., 2010). Treg is involved in bacterial persistence, increased in *H. pylori*-associated gastritis, and even positively related with the grade of chronic inflammation and the number of lymphoid follicles (Jang 2010). Treg is also markedly elevated in patients with GC compared to those with chronic gastritis and gastric dysplasia. Additionally, *H. pylori* may direct immunosuppression of T cells and regulate the host immune responses through activation of Treg and dendritic cells (Blanchard et al., 2004).

Macrophages are essential components of innate immunity, and their apoptosis will impair the host mucosal defense to microbes (Asim et al., 2010). *H. pylori* infection leads to a rapid infiltration of macrophages into the mouse stomach. *H. pylori* also activates TLR-2 and TLR-4 in macrophages, and subsequently induces the secretion of distinct cytokines including IL-2, IL-6 and IFN- α (Obonyo et al., 2007). However, the bacteria remain viable when internalized by GECs or even macrophages, which indicates the killing defects in the host due to inhibition of the phagosome maturation (Keep et al., 2010). In addition, *H. pylori* induces the formation of a specific phospho-c-Fos c-Jun activator protein-1 (AP-1) complex in gastric macrophages by an ERK-dependent way, that causes apoptosis and contributes to immune escape of the germ (Asim et al., 2010).

Several *H. pylori* proteins can impair macrophage and T cell functions *in vitro* through unclear mechanisms (Zabaleta et al., 2004). VacA, known as a toxic protein with vacuolating activity, can induce apoptosis in GECs, affect antigen presentation by B lymphocytes, inhibit T cell activation and proliferation, and modulate the T cell-mediated cytokine responses, which mainly target the adapted immune system (Gebert et al., 2004). CagA is also capable of preventing hydroxyurea-induced B-cell apoptosis by reducing p53 accumulation (Umehara et al., 2003). The arginase may impair T cell functions through inhibiting proliferation and the TCR zeta-chain (CD3zeta) expression, besides its role in urea production (Zabaleta et al., 2004).

4.3 Network of cytokines

H. pylori-stimulated host inflammatory and immune responses lead to release of a large amount of cytokines, which contribute to the loss of balance between cell proliferation and apoptosis prior to many gastric lesions including AG and GC. There is a shift from Th1 (IFN- γ , TNF- α and IL-12) towards Th2 (IL-4, IL-10 and IL-6)-type immune response in patients with GC and dysplasia (Marotti et al., 2008). IL-13 is recently described as a central mediator of Th2-dominant immune response and may be implicated in different outcomes of *H. pylori* infection (Marotti et al., 2008). TGF- β and IL-10 are two vital anti-inflammatory cytokines that regulate mucosal immunity in various infectious diseases (Wu et al., 2007). The local and systemic T-cell response in Hp-GC patients is mainly characterized by production of IL-10 (Lundin et al., 2007). When stimulated with *H. pylori* antigens, T cells from both peripheral blood and gastric mucosa produce significantly higher amounts of IL-10 in Hp-GC patients than in *H. pylori*-infected asymptomatic subjects. In addition, the

frequency of activated CD8 (+) T cells is markedly reduced in stomach mucosa of GC patients compared to asymptomatic individuals (Lundin et al., 2007). Therefore, the increased production of the suppressive cytokine IL-10 in Hp-GC patients may lead to a diminished local cytotoxic anti-tumor T-cell response and even contributes to cancer progression.

A predominant *H. pylori*-specific Th1 response associates with peptic ulcer, whereas combined secretion of both Th1 and Th2 cytokines are present in simple gastritis (D'Elcios et al., 2005). In *H. pylori*-infected mice, the local Th1-type response might alter the systemic Th1/Th2-type cytokine balance under particular physiopathological conditions of active tissue and/or vascular formation, such as pregnancy (Rossi et al., 2004). *H. pylori* neutrophil-activating protein is able to recruit leukocytes and stimulate neutrophils or monocytes to release IL-12, a key cytokine for the differentiation of naive Th cells into the Th1 phenotype (D'Elcios et al., 2007). During *H. pylori* infection, activated macrophages produce IL-18, which stimulates the IFN- γ secretion by NK and T cells (Kawabata et al., 2001). Nevertheless, Th1 immune response in the stomach may destroy the proliferation / apoptosis balance and promote the severity of *H. pylori*-induced gastric lesions (Xia et al., 2001; Vivas et al., 2008).

In the host, the innate immune response usually represents by TLRs and Nod-like receptors that recognize their specific ligands, activate transcription factors including NF- κ B, AP-1 and CREB-1, and induce inflammatory cytokines such as IL-8, IL-12, IL-6, IL-1 β , IL-18, TNF- α and IL-10 (Sánchez-Zauco et al., 2010). Amounts of the tumor suppressor p53 and the major innate immune hub protein TRAF-6 reduce in *H. pylori*-infected gastric cells, and coincide with a partially cagPAI-dependent decrease in the expression and activity of deubiquitinating enzyme USP7, which indicates that *H. pylori* may also influence some immunity-associated cytokines through interfering in the host ubiquitin pathways (Coombs et al., 2010).

During *H. pylori* infection, significant overexpression of MHC II antigen-presenting genes, IL-7R ubiquitin-D, CXCR4, lactoferrin immune response-related genes, CXCL-2 and -13, CCL18 chemokine ligand, and VCAM-1 genes have been established (Galamb et al., 2008). In addition, IL-23p19 up-regulation is confirmed in gastric biopsies from both *H. pylori* infected-mice and patients with chronic gastritis (Vivas et al., 2008). CCR6 is markedly upregulated in CD3 (+) T cells infiltrating the gastric mucosa and has been reported to mediate lymphocyte homeostasis and immune responses in mucosal tissue (Wu et al., 2007; Tsai & Hsu, 2010). CCL20, the ligand to CCR6, selectively expresses in inflamed stomach tissues and is upregulated in response to *H. pylori* in GECs stimulated by IL-1 β and TNF- α . Furthermore, recombinant CCL20 induces lymphocyte chemotaxis migration in fresh gastric T cells *in vitro* (Wu et al., 2007). The interaction between CCR6 and CCL20 plays a potential role in recruiting T cells to inflamed gastric epithelium during *H. pylori* infection (Tsai & Hsu, 2010).

4.4 Autoimmune and immune tolerance

H. pylori has evolved means to structurally alter its surface characteristics to evade innate and adaptive immune responses (Nilsson et al., 2006). *H. pylori* expresses mimicry of some ABO blood group antigens (Moran et al., 2010). Additionally, CagA, VacA and BabA can mimic and bind to specific receptors or surface molecules on GECs and platelets (Höcker & Hohenberger 2003; Takahashi et al., 2004; Hennig et al., 2004; Baldari et al., 2005). It has been shown that anti-CagA, anti-VacA and anti-BabA antibodies targeting both *H. pylori* components and host mimic molecules can be detected in the majority of GC patients with

increased levels (Rudi et al., 1997; Vaucher et al., 2000; Sokic-Milutinovic et al., 2004). *H. pylori* LPS is of underacylation and underphosphorylation and has significantly lower endotoxic and immuno-activities, which may lead to the infection chronicity (Moran et al., 2010). *H. pylori* produces LPS O-antigen units that can be posttranslationally fucosylated to generate Lewis antigens, which are also found on human GECs, and this molecular mimicry induces autoreactive antibodies (Nilsson et al., 2006). Circulating anti-Lewis antibody is detected in the sera of GC patients but not in *H. pylori*-negative control subjects (Hynes et al., 2005). Absorption of the sera with outer membrane vesicles decreases anti-Lewis autoantibody level. The ability of these vesicles to absorb anti-Lewis autoantibody indicates that they partly play a role in putative autoimmune aspects of *H. pylori* pathogenesis (Hynes et al., 2005).

As reported, C57BL/6 mice infected with CagA (+) *H. pylori* during the neonatal period tend to be protected from preneoplastic lesions, compared to those infected with the same strain at 5-6 weeks of age (Arnold et al., 2011). This protection results from the development of *H. pylori*-specific peripheral immunologic tolerance, which is mediated by long-lived inducible Treg and controls the local CD4 (+) T-cell responses that trigger premalignant transformation. Moreover, both the biased ratio of Treg to T-effector cells in the neonatal period and prolonged low-dose exposure to antigens contribute to the development of immune tolerance to *H. pylori* (Arnold et al., 2011). In addition, exposure of cells to most microbial pathogens can up-regulate HSPs, whereas *H. pylori* decreases expression of HSPs including HSP8, HSP70, HSP60, and heat shock factor 1 (HSF-1). The down-regulation of HSPs may be a mechanism of immune evasion that promotes chronic *H. pylori* infection (Axsen et al., 2009). NO / iNOS as one part of the host innate defense system, determines the killing efficiency of *H. pylori* by macrophages. *H. pylori* up-regulates arginase II (Arg2) expression, resulting in reduction of NO / iNOS production and decreased killing of the germ by macrophages, which implicates another potential mechanism of the immune evasion of *H. pylori* (Lewis et al., 2010).

5. Genetic and phenotypic alterations

Some polymorphisms of certain genes including IL-1, IL-4, IL-6, IL-8, IL-10, TNF, iNOS and COX-2, which likely differ in various host species, play important roles in the inflammation, immune responses, and gastric carcinogenesis, besides in susceptibility to *H. pylori* infection. The GC risk-associated alleles are more prevalent in certain subjects of special human races, geographic regions, and *H. pylori* infection status. Thus, genetic and phenotypic backgrounds of *H. pylori* may interact with mentioned host factors and influence the related biological or pathological processes.

5.1 IL-1

IL-1 β and IL-1RN polymorphisms relate to the development of GC and *H. pylori* infection markedly increases the risk, which supports the association of these polymorphisms with risk of Hp-GC (Al-Moundhri et al., 2006). Either infection with vacA s1 (+), vacA m1 (+) and cagA (+) strains or the host genotype of IL-1 β -511T homozygous for IL-1RN2/2 allele is associated with an increased GC risk (Figueiredo et al., 2002). Individuals with polymorphisms in IL-1 and TNF- α genes have the highest risk of GC, when they are simultaneously infected by virulent *H. pylori* strains of cagA (+), vacA s1 (+), vacA m1 (+) and babA2 (+). As for IL-1 gene, the odds of developing GC are greatest in those with

combination of high-risk bacterial / host genotypes such as *vacA* s1 / IL-1 β -511T, *vacA* m1 / IL-1 β -511T, *cagA* (+) / IL-1 β -511T, *vacA* s1 / IL-1RN2/2, *vacA* m1 / IL-1RN2/2, and *cagA* (+) / IL-1RN2/2 (Figueiredo et al., 2002).

IL-1 β -511T/-31C (+) and IL-1RN2 (+) polymorphisms are associated with severe degrees of inflammation, prevalence of IM and AG, and increased expression of IL-1 β , which plays a central role in GC development (Rad et al., 2004). The combined prevalence of *H. pylori* infection and IL-1 β -511T genotype has a strong association with GC risk in both Latino and Chinese populations (Morgan et al., 2006; Feng et al., 2008). The IL-1 β -511T/T carrier status enhances hypermethylation of multiple CpG island loci and increases the risk for Hp-GC of non-cardiac type as an independent risk factor in a Chinese population (Li et al., 2007; Yoo et al., 2010). IL-1 β -511C allele is related with increased risk of AG and GC in Peru (Gehmert et al., 2009). IL-1 β -511C/C polymorphism enhances IL-1 β production in the antrum, and involves in the development of nHp-GC in North Indian (Kumar et al., 2009). In a Korean population, combined effects of *H. pylori* infection and IL-1 β -511C/-31T polymorphisms with enhanced mucosal IL-1 β production contribute to the development of intestinal-type GC (Chang et al., 2005). IL-1 β -511CC/-31TT variants also increase GC risk in a Chinese population, especially of those with *H. pylori* infection (Yang et al., 2004). Nevertheless, IL-1 β -511/-31 alleles are not associated with GC risk in Japan and IL-1 β -511T-to-C genotype is not associated with GC in a multistep carcinogenesis model (Kato et al., 2001; Sugimoto et al., 2007). In addition, none of the variants of IL-1 β -511C>T, -31T>C, -1464G>C and -3737C>T, is individually or in its haplotype configuration linked to GC in a Caucasian population (Wex et al., 2010).

IL-1 β -31C/+3954T haplotypes are more likely detected with IM or dysplasia of the stomach and relate to GC risk in African Americans, but not in Caucasians, Swedes and Italians (Palli et al., 2005; Camargo et al., 2006; Persson et al., 2009; Zabaleta et al., 2011). In Mexico, IL-1 β -31C allele increases high-grade dysplasia and is an independent risk factor for GC (Garza-González et al., 2003). The IL-1 β -31CC carriers have an increased risk of intestinal-type GC among *CagA*-positive subjects, compared to those with IL-1 β -31TT. Among *CagA*-negative subjects, however, there is no mentioned association (Sicinski et al., 2006). IL-1 β 1473C>G is significantly associated with GC among Koreans (Lee et al., 2004). In Japan, IL-1 β +3953 polymorphism can influence the cancer risk of gastric corpus (Sakuma et al., 2005). Carriers of IL-1 β +3954T or IL-1RN2 heterozygote allele cause increased GC risk in a Costa Rican population, although IL-1 β -31, IL-1 β -511 and IL-10 polymorphisms do not (Alpízar-Alpízar et al., 2005).

IL-1RN1/2 genotype is significantly and independently associated with GC (Erzin et al., 2008). IL-1RN2 allele relates to GC especially in *H. pylori*-positive patients of an Omani Arab population (Al-Moundhri et al., 2006). In Italy, multivariate analyses have shown a notable increase in GC risk for the IL-1RN2 / IL-1 β -31T haplotype carriers (Palli et al., 2005). *H. pylori*-infected individuals with carriers of IL-1RN2 show high risks for both intestinal and diffuse types of GC in Asia (Chen et al., 2004). IL-1RN2 and IL-1 β -511T may contribute to intestinal GC in the absence of concomitant *H. pylori* infection (Ruzzo et al., 2005). IL-1RN2/2 and IL-1 β -31C genotypes relate to higher GC risk in Caucasians (Garza-González et al., 2003). The IL-1RN2/2 genotype is strongly associated with early-stage GC, and involves in the development of nHp-GC in North Indian (Glas et al., 2004; Kumar et al., 2009). IL-1RN 2R/2R and Ex5-35C genotypes are related to an increased risk of Hp-GC of non-cardia type (Crusius et al., 2008). However, IL-1 β -511, IL-1RN and IL-2 polymorphisms do not significantly contribute to GC in Korean patients (Shin et al., 2008). In Mexico, IL-1RN2/2 is also not associated with either high-grade dysplasia or risk of GC (Garza-González et al., 2003).

5.2 IL-10

As for subtypes of GC in Taiwanese Chinese, the high IL-10 producer genotype is significantly linked with the risk of cardia type or advanced stage (Wu et al., 2003). The ATA/GCC haplotype of IL-10 -1082/-819/-592 significantly increases GC risk compared with ATA/ATA haplotype (Sugimoto et al., 2007). The -1082G/-819C/-592C alleles (GCC haplotype) usually lead to higher mucosal IL-10 mRNA level than ATA haplotype and are associated with colonization by more virulent *H. pylori* strains of *cagA* (+), *vacA* s1 (+), and *babA2* (+) (Rad et al., 2004). IL-10 -1082 AG+GG but not -819 or -592 polymorphisms, markedly increase GC risk in China, especially in patients with *H. pylori* infection (Xiao et al., 2009). In a low prevalence province of China, the -1082G* allele is related with significantly increased risk of Hp-GC, whereas the higher susceptibility to GC in -1082 AG+GG genotype does not show a synergism with *H. pylori* status in another population of northern China (Bai et al., 2008). In Korean, the frequency of -1082G carriers is higher in diffuse-type GC or benign gastric ulcer (BGU), regardless of *H. pylori* infection (Kang et al., 2009). Moreover, IL-10 -819CC and IL-1RN 9589TT genotypes are of inverse association with *H. pylori* seropositivity among cases with chronic AG, an established precursor of GC (Gao et al., 2009). The IL-10 819C allele is related with IM in *H. pylori*-positive subjects of a Singapore-Chinese population (Zhu et al., 2009).

In *H. pylori*-infected Japanese, the frequency of -592AA homozygote showing concomitant carriage of HLA DRB1*0405-DQB1*0401 is notably higher in intestinal-type GC. In addition, the HLA class II and -592A/C polymorphism synergistically affect the susceptibility to GC (Ando et al., 2009). IL-10 -592C/A, IL-1 β +3954T/C and IL-1RN*2/L are individually associated with GC in Costa Rican regions, and a combination of these cytokine polymorphisms with *H. pylori vacA* s1b / m1 genotypes further increased the risk (Con et al., 2009). IL-10 -592/-1082 alleles are not linked with high-grade dysplasia or GC risk in a Mexican population, though relate to high GC risk in Caucasians; whereas carriers with two or more risk-associated alleles of IL-10 -592C, IL-1 β -31C and IL-1RN2 are at increased risk for intestinal-type GC in Mexico, compared to those with 0 or 1 mentioned allele (Garza-González et al., 2003). In Korean, the presence of IL10 -592C/A as opposed to A/A is one of risk factors for IM. The -592CC is associated with more than doubling of the risk for intestinal-type GC. Furthermore, a synergistic effect has been observed between IL-10 -592A/A and IL-8 -251A/A with respect to the development of GC or BGU (Kang et al., 2009). IL-10 -819C and -592C alleles are associated with increased GC risk in Japan, but -1082 polymorphism not (Sugimoto et al., 2007). The -819TT genotype relates to IM and non-cardia GC in an Italian population (Zambon et al., 2005).

Data from Korea have even suggested that the association between IL-10 genetic polymorphisms and GC risk is modified by soybean product intake (Ko et al., 2009). The combined effect between low intake of soybean products and -1082AG/GG, -819TC/CC or -592GG/GA variants will increase the risk for GC. As for subgroups, the CCG haplotype has an increased risk of GC relative to ATA haplotype among subjects with low intake of soybean products (Ko et al., 2009).

5.3 IL-4, IL-6 and IL-8

There is a moderately increased risk for Hp-GC of non-cardia type in IL-4R -29429T variant (Crusius JB et al., 2008). In Taiwanese Chinese, a higher risk of developing cardia or diffuse-type GC is observed for the carrier of IL-4 -590CT/CC genotype (Wu et al., 2003). IL-4 -168C and -590T alleles and IL-6 -174G/G haplotype significantly relate to the risk of non-cardia

GC (Sugimoto et al., 2010). The IL-6 -174G allele is markedly higher in patients with GC than those with chronic gastritis (Gatti et al., 2007).

IL-8 -251A allele significantly increases the risk of gastric dysplasia in Venezuelan subjects, especially of those infected with CagA (+) *H. pylori*, which suggests a role of interactions between host and bacterial genetic factors in the development of precancerous lesions (Kato et al., 2006). Similarly in a Mexican population, the -251A genotype has a significant effect on the prevalence of dysplasia and may be related to distal GC, especially when *H. pylori* CagA is present (Garza-Gonzalez et al., 2007). IL-8 -251A/T allele and polymorphisms in vacA gene are involved in limiting the infection outcome to gastritis and peptic ulcer or in favoring cancer onset in Iranian patients (Kamali-Sarvestani et al., 2006). The -251T>A polymorphism is usually associated with higher IL-8 expression, severe neutrophil infiltration and increased risk of AG and GC in Japan, but not with GC risk in a Portuguese population (Taguchi et al., 2005; Canedo et al., 2008). The IL-8 -251A polymorphism may be associated with progression of AG in *H. pylori*-infected patients, and increase the risks for GC and gastric ulcer in Japanese people (Ohyauchi et al., 2005). The -251A/A genotype, which is more common in *H. pylori*-positive patients with GC or BGU than in *H. pylori*-positive controls, increases the risk for upper-third location, diffuse, poorly differentiated, lymph node and liver metastasis, and p53-mutated subtypes of GC (Taguchi et al., 2005; Kang et al., 2009). The high-risk IL-8 -251T allele is related with >2-fold increased risk for GC of diffused and mixed types (Lee et al., 2005). In addition, the -251T/T genotype significantly relates to increased risk of GC with high frequency of microsatellite instability (Shirai et al., 2006).

5.4 TNF

Polymorphisms of TNF- α -857TT and -1031TT, besides CD14, CXC chemokine receptor 2 (CXCR2), IL-1 RI, NF- κ B2, and TLR-4, have the potential to influence persistent *H. pylori* infection (Hamajima et al., 2003). TNF- α -857T/-863A/-1031C alleles are associated with increased risks for gastric ulcer and GC in Japan (Sugimoto et al., 2007). In a Korean population, the -857C/T variant is independently and significantly related to an increased risk of GC regardless of smoking status. However, all haplotype-pairs including TCT or CCC of -863C/A and -1031T/C are linked with a higher GC risk only among smokers (Yang et al., 2009). TNF- α -308 genotypes correlate to higher risk of GC in Caucasians, but not to high-grade dysplasia or increased risk of GC in Mexican population (Garza-González et al., 2003). The -308A allele increases the risk for GC development but is only weakly associated with the early-stage diffuse-type GC (Glas et al., 2004). The -308G/A haplotype relates to an increased IL-8 expression and the susceptibility to GC in several studies. In Poland, GC risk is dramatically relevant to the TNF- α -308G>A and IFN- γ R2 Ex7-128C>T polymorphisms, but not to IL-1 α -889C>T and IL-12 α IVS2-798T>A, IVS2-701C>A and Ex7+277G>A variants (Hou et al., 2007). Risk of GC is also markedly elevated in Chinese subjects carrying the TNF- α -308 AG genotype (Lu et al., 2005). In addition, polymorphisms in TNF- β (*A and +252G/G) and HSP70-1 (*C and +190C/G) show a significant gene-dose effect as risk markers from preneoplastic lesions to GC in Mexican (Partida-Rodríguez et al., 2010).

5.5 Other cytokine genes

NOS2 -954G/C (especially -954GC+CC) polymorphism but not Ser608Leu is associated with higher risk of GC in a Brazilian population (Jorge et al., 2010). The iNOS C150T is related with the risk of Hp-GC, but not with gastric atrophy or *H. pylori* seropositivity in a Japanese population. Considering the location of GC, there are significant differences between the

controls and non-cardia group for iNOS -150C/T and C/T + T/T (Goto et al., 2006). The iNOS promoter polymorphism of long CCTTT repeat notably upregulates its mRNA level and leads to increased risk of intestinal-type GC in Japanese women, especially of those with IL-1 β -31 polymorphism and without smoking history (Tatemichi et al., 2005).

In the high incidence Hexi area of Gansu Province in China, COX-2 -899G>C polymorphism may be a risk factor for GC, and the -899C carrier genotype and *H. pylori* infection possibly have a synergistic effect on GC. However, COX-2 587G>A is not related with GC risk (Zhu et al., 2011). COX-2 -1195AA polymorphism also plays an important role in developing GC in another high-risk Chinese population (Zhang et al., 2006). COX-2 -765G>C polymorphism might be a marker for genetic susceptibility to GC in northern India, regardless of *H. pylori* infection (Saxena et al., 2008). Moreover, the lymphotoxin- α NcoI A/G heterozygous genotype correlates to *H. pylori* infection in noncardia GC patients of Chinese Han population (Li et al., 2005). And in Cauca population, the glutathione S-transferase M1 homozygous deletion polymorphism is related to increased GC risk (Torres et al., 2004).

6. Beneficial edge of the sword

In recent years, increasing data have indicated that patients with Hp-GC prospectively have a better outlook than those with nHp-GC (Meimarakis et al., 2006; Marrelli et al., 2009). *H. pylori* infection must play certain roles as the other edge of the sword, which is beneficial for the host and counteracts its harmfulness in pathological lesions including gastritis, GC, and lymphoma. However, up to date, the corresponding studies and results are still limited because of multiple influencing factors including traditional unilateral opinions.

The positive interaction between *H. pylori* and the host should be the radical factor in leading to changes of local and system immune responses. There is a high *H. pylori* prevalence but a low GC risk in *H. pylori*-infected than in uninfected Mexican children, which may be attributed to significantly higher infiltration of macrophages and T and B cells, a balanced increase of CD4, CD8, and CD20 lymphocytes, but decreased levels of activated mast cells, neutrophil and mononuclear cells (Muñoz et al., 2007). During *H. pylori* infection, both the number of local CD4 (+) T cells and MHC II expression by the GECs increase, and GECs can process and present antigens to CD4 (+) T cells as a new kind of local antigen presenting cells (APC) (Barrera et al., 2002). Therefore, *H. pylori* infection in the host may alter natural immune mechanisms against cancer.

The humeral immune response induced by *H. pylori* is predominately IgG1 subclass (suggestive of a Th2 response) and likely protects against the development of GC, although it is not essential for bacterial eradication (Segal et al., 2001). As reported, the antibody level of anti-Thomsen-Friedenreich antigen (TAg) in GC patients is significantly lower than that in normal blood donors (Klaamas et al., 2002). However, TAg-specific IgG immune response is up-regulated exclusively in *H. pylori*-infected individuals, which may contribute to the significantly better survival of Hp-GC patients at early stage than that of nHp-GC ones at the same stage. Better survival is also noted in *H. pylori* seropositive IgM strong responders at approximately 40-60 months of observation, though the anti-T IgM level is not significantly related to the survival (Kurtenkov et al., 2003). In addition, the stimulation of *H. pylori*-related autoantibodies in antigen processing and presentation and subsequent T-cell activation and proliferation improves host immune status. On the other hand, in an autoimmune response, autoantibodies can induce the cross-reaction against those localized

or circulating GC cells, which are characterized by mimic or absorbed *H. pylori* antigens, and lead to the killing and even suppressing of metastasis of cancer cells (Xue et al., 2008). Thus, it is hypothesized that autoimmune responses induced by *H. pylori* components may help improve the prognosis of GC patients.

Several models, including delayed type hypersensitivity in immune mice, and spontaneous clearance of *H. pylori* from IL-10 and phagocyte oxidase mice, provide evidence that severe inflammation may be sufficient to eradicate the germ (Blanchard et al., 2004). *H. pylori* LPS can dramatically initiate inflammatory responses and cause severe pathological changes not only *in vitro* but also *in vivo*. However, increased levels of TNF- α and IL-10, as well as a strong antigen specific Th1 response including, IFN- γ , IL-2 and high IgG2a serum titers are simultaneously observed in mice inoculated with *H. pylori* LPS+ sonicate. Mice that received LPS- sonicate are strongly Th2 biased in their immune response, with significantly more IL-4 than IFN- γ and serum IgG1 titers higher than IgG2a (Taylor et al., 2006). Accordingly, *H. pylori*-induced inflammatory responses potentially have positive functions in resisting certain cancer-advancement-related biological processes post the development of GC and showing better outlook in those patients, although they have played fundamental roles during the phase of cancer formation.

Interestingly, the COX-2 expression induced by *H. pylori* still seems to be able to attenuate the degree of AG, the initial event of GC, though it plays a role in gastric carcinogenesis (Hahm et al., 2002). COX-2-dependent PGE2 also shows a protective effect during the oncogenic process of Hp-GC in that it can prevent *H. pylori*-induced gastric preneoplasia and reverse preexisting lesions by suppressing IFN- γ expression (Toller et al., 2010). As confirmed, the protective effect is always accompanied by increased bacterial colonization in models, which is attributed to the IL-2-dependent immunosuppressive effects of PGE2 on CD4 (+) Th1 cells in migration, proliferation and cytokine secretion. Therefore, PGE2 has an important immunomodulatory role during *H. pylori* infection, preventing excessive local immune responses and the associated immunopathology by inhibiting the effector functions of pathogenic Th1 cells (Toller et al., 2010).

Certain genetic and phenotypic polymorphisms also show beneficial effects in improving the prognosis of GC patients, which might differ in various populations and need further confirmation. IL-6 -572G carrier is found to have a protective effect against IM development as compared with C/C (Kim et al., 2008). IL-8 -251AA genotype confers a decreased risk for Hp-GC of non-cardia type, mainly of the intestinal type (Crusius et al., 2008). IL-10 -592C/C is an independent factor associated with a decreased risk of intestinal-type GC by multivariate analysis (Kang et al., 2009). When analyzed together with host genetic factors, the presence of the IL-1 β -31TT genotype emerges as a protective factor against gastric malignant disorders (Erzin et al., 2008). Based on a review of 25 case-control studies in Caucasian, Asian and African populations, IL-1 β and NAT1 variants are most consistently associated with increased GC risk, which may account for up to 48% of attributable risk of GC, but HLA-DQ, TNF and CYP2E polymorphisms may confer certain protection against GC (González et al., 2002). However, a comprehensive analysis of 207 SNPs of 11 Cytokine genes including IL-1 α , IL-1 β , IL-1RN, IL-4, IL-4R, IL-8, IL-10, IL-12, TNF- α , TNF- β , and IFN- γ , has revealed that just variations in IL-4 (984 and 2983 AA/GA) and IL-1RN (-1102 and 6110 CG/GA) diplotypes are negatively associated with the risk of Hp-GC (Seno et al., 2007).

7. Conclusion

The majority of GC relates to chronic inflammation induced by *H. pylori* infection, in which many bacterial virulence factors including Cag PAI, VacA, OMP, LPS, urease, IceA, and flagella components participate with fundamental roles through a complex network of inflammatory cytokines, multiple signalling pathways, and even some genetic or phenotypic polymorphisms of the host. Gastric carcinogenesis, especially of the intestinal-type tumor, is a multistep process of mucosal alterations leading from gastritis via glandular atrophy, IM and dysplasia to invasive carcinoma (Bornschein et al., 2010). There is a potential 'point of no return' during this process, which means a situation when certain alterations are no longer reversible by *H. pylori* eradication and progression to GC have to continue (Vieth et al., 2006; Bornschein et al., 2010). Thus, the gastric carcinogenesis is actually divided into two phases; one is of reversible pre-the-'point of no return', and the other is of irreversible post-the-'point of no return'. During the first phase, *H. pylori* works with more roles as a confirmed carcinogen according to traditional opinion; whereas in the second phase, the inflammation has been switched to *H. pylori*-independent carcinogenesis with GC as the destination.

Considering the host-bacterium cross-talk background and described double functions of both inflammatory / immune responses and genetic / phenotypic polymorphisms, a novel angle should be adopted to analyze the roles of *H. pylori* as a double-edged sword in GC. *H. pylori* is more harmful in promoting carcinogenesis prior to the 'point of no return', however, may be more beneficial for improving the host outlook post the development of GC. Based on this theory, *H. pylori* eradication may be performed at proper stage to protect against GC, and more efficient vaccines of prophylaxis and therapeutic ones might be designed and used to prevent the advancement of GC and improve the prognosis, which needs further confirmation by large from-bench-to-bed studies.

8. Acknowledgement

This work is supported by a grant from the National Natural Science Foundation of China (No.30901733).

9. References

- Akhiani AA. The role of type-specific antibodies in colonization and infection by *Helicobacter pylori*. *Curr Opin Infect Dis*. 2005;18(3):223-7.
- Al-Moundhri MS, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Madhani A, Ganguly SS, Al-Yahyaee SA, Grant CS. Interleukin-1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab population. *Gastric Cancer*. 2006;9(4):284-90.
- Alpizar-Alpizar W, Pérez-Pérez GI, Une C, Cuenca P, Sierra R. Association of interleukin-1B and interleukin-1RN polymorphisms with gastric cancer in a high-risk population of Costa Rica. *Clin Exp Med*. 2005;5(4):169-76.
- Ando T, Ishikawa T, Kato H, Yoshida N, Naito Y, Kokura S, Yagi N, Takagi T, Handa O, Kitawaki J, Nakamura N, Hasegawa G, Fukui M, Imamoto E, Nakamura C, Oyamada H, Isozaki Y, Matsumoto N, Nagao Y, Okita M, Nakajima Y, Kurokawa M, Nukina M, Ohta M, Mizuno S, Ogata M, Obayashi H, Park H, Kitagawa Y,

- Nakano K, Yoshikawa T. Synergistic effect of HLA class II loci and cytokine gene polymorphisms on the risk of gastric cancer in Japanese patients with *Helicobacter pylori* infection. *Int J Cancer*. 2009;125(11):2595-602.
- Appelmelk BJ, Vandenbroucke-Grauls CMJE. Lipopolysaccharide Lewis Antigens. In: Mobley HLT, Mendz GL, Hazell SL, editors. *Helicobacter pylori: Physiology and Genetics*. Washington (DC): ASM Press; 2001. Chapter 35.
- Arnold IC, Lee JY, Amieva MR, Roers A, Flavell RA, Sparwasser T, Müller A. Tolerance rather than immunity protects from *Helicobacter pylori*-induced gastric preneoplasia. *Gastroenterology*. 2011;140(1):199-209.
- Asim M, Chaturvedi R, Hoge S, Lewis ND, Singh K, Barry DP, Algood HS, de Sablet T, Gobert AP, Wilson KT. *Helicobacter pylori* induces ERK-dependent formation of a phospho-c-Fos c-Jun activator protein-1 complex that causes apoptosis in macrophages. *J Biol Chem*. 2010;285(26):20343-57.
- Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific vacA types with cytotoxin production and peptic ulceration. *J Biol Chem*. 1995;270(30):17771-7.
- Axsen WS, Styer CM, Solnick JV. Inhibition of heat shock protein expression by *Helicobacter pylori*. *Microb Pathog*. 2009;47(4):231-6.
- Bagnoli F, Buti L, Tompkins L, Covacci A, Amieva MR. *Helicobacter pylori* CagA induces a transition from polarized to invasive phenotypes in MDCK cells. *Proc Natl Acad Sci USA* 2005; 102(45): 16339-44.
- Bai XL, Sun LP, Liu J, Chen W, Zhang Y, Yuan Y. [Correlation of interleukin-10-1082G/a single nucleotide polymorphism to the risk of gastric cancer in north China: a case-control study]. *Ai Zheng*. 2008;27(1):35-40.
- Baldari CT, Lanzavecchia A, Telford JL. Immune subversion by *Helicobacter pylori*. *Trends Immunol* 2005; 26(4): 199-207.
- Barrera C, Espejo R, Reyes VE. Differential glycosylation of MHC class II molecules on gastric epithelial cells: implications in local immune responses. *Hum Immunol*. 2002;63(5):384-93.
- Beales IL. Effect of interleukin-1beta on proliferation of gastric epithelial cells in culture. *BMC Gastroenterol*. 2002;2:7.
- Becher D, Deutscher ME, Simpfendorfer KR, Wijburg OL, Pederson JS, Lew AM, Strugnell RA, Walduck AK. Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against *Helicobacter pylori* in mice. *Eur J Immunol*. 2010;40(10):2778-90.
- Beswick EJ, Reyes VE. Macrophage migration inhibitory factor and interleukin-8 produced by gastric epithelial cells during *Helicobacter pylori* exposure induce expression and activation of the epidermal growth factor receptor. *Infect Immun*. 2008;76(7):3233-40.
- Blanchard TG, Drakes ML, Czinn SJ. *Helicobacter* infection: pathogenesis. *Curr Opin Gastroenterol*. 2004;20(1):10-5.
- Bornschein J, Kandulski A, Selgrad M, Malfertheiner P. From gastric inflammation to gastric cancer. *Dig Dis*. 2010;28(4-5):609-14.
- Bronte-Tinkew DM, Terebiznik M, Franco A, Ang M, Ahn D, Mimuro H, Sasakawa C, Ropeski MJ, Peek RM Jr, Jones NL. *Helicobacter pylori* cytotoxin-associated gene A

- activates the signal transducer and activator of transcription 3 pathway *in vitro* and *in vivo*. *Cancer Res.* 2009;69(2):632-9.
- Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J. *Helicobacter felis* eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. *Gastroenterology.* 2005;128(7):1937-52.
- Camargo MC, Mera R, Correa P, Peek RM Jr, Fontham ET, Goodman KJ, Piazuelo MB, Sicinschi L, Zabaleta J, Schneider BG. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2006;15(9):1674-87.
- Canedo P, Castanheira-Vale AJ, Lunet N, Pereira F, Figueiredo C, Gioia-Patricola L, Canzian F, Moreira H, Suriano G, Barros H, Carneiro F, Seruca R, Machado JC. The interleukin-8-251*T/*A polymorphism is not associated with risk for gastric carcinoma development in a Portuguese population. *Eur J Cancer Prev.* 2008;17(1):28-32.
- Chang YJ, Wu MS, Lin JT, Chen CC. *Helicobacter pylori*-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. *J Immunol.* 2005;175(12):8242-52.
- Chang YJ, Wu MS, Lin JT, Sheu BS, Muta T, Inoue H, Chen CC. Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by *Helicobacter pylori* involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. *Mol Pharmacol.* 2004;66(6):1465-77.
- Chang YW, Jang JY, Kim NH, Lee JW, Lee HJ, Jung WW, Dong SH, Kim HJ, Kim BH, Lee JI, Chang R. Interleukin-1B (IL-1B) polymorphisms and gastric mucosal levels of IL-1beta cytokine in Korean patients with gastric cancer. *Int J Cancer.* 2005;114(3):465-71.
- Chen A, Li CN, Hsu PI, Lai KH, Tseng HH, Hsu PN, Lo GH, Lo CC, Lin CK, Hwang IR, Yamaoka Y, Chen HC. Risks of interleukin-1 genetic polymorphisms and *Helicobacter pylori* infection in the development of gastric cancer. *Aliment Pharmacol Ther.* 2004;20(2):203-11.
- Chen CN, Hsieh FJ, Cheng YM, Chang KJ, Lee PH. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer. *J Surg Oncol.* 2006;94(3):226-33.
- Cho SO, Lim JW, Kim KH, Kim H. Involvement of Ras and AP-1 in *Helicobacter pylori*-induced expression of COX-2 and iNOS in gastric epithelial AGS cells. *Dig Dis Sci.* 2010;55(4):988-96.
- Churin Y, Al-Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M. *Helicobacter pylori* CagA protein targets the c-Met receptor and enhances the motogenic response. *J Cell Biol.* 2003;161(2):249-55.
- Con SA, Takeuchi H, Con-Chin GR, Con-Chin VG, Yasuda N, Con-Wong R. Role of bacterial and genetic factors in gastric cancer in Costa Rica. *World J Gastroenterol.* 2009;15(2):211-8.
- Coombs N, Sompallae R, Olbermann P, Gastaldello S, Göppel D, Masucci MG, Josenhans C. *Helicobacter pylori* affects the cellular deubiquitinase USP7 and ubiquitin-regulated components TRAF6 and the tumour suppressor p53. *Int J Med Microbiol.* 2011;301(3):213-24.

- Crusius JB, Canzian F, Capellá G, Peña AS, Pera G, Sala N, Agudo A, Rico F, Del Giudice G, Palli D, Plebani M, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Pala V, Save VE, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martínez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, Bingham S, Caldas C, Linseisen J, Kaaks R, Overvad K, Tjønneland A, Büchner FC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Rinaldi S, Ferrari P, Riboli E, González CA. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). *Ann Oncol*. 2008;19(11):1894-902.
- D'Elíos MM, Amedei A, Benagiano M, Azzurri A, Del Prete G. *Helicobacter pylori*, T cells and cytokines: the "dangerous liaisons". *FEMS Immunol Med Microbiol*. 2005;44(2):113-9.
- D'Elíos MM, Montecucco C, de Bernard M. VacA and HP-NAP, Ying and Yang of *Helicobacter pylori*-associated gastric inflammation. *Clin Chim Acta*. 2007;381(1):32-8.
- Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. *Hepatology*. 2009;49(5 Suppl):S56-60.
- Dong LM, Shu XO, Gao YT, Milne G, Ji BT, Yang G, Li HL, Rothman N, Zheng W, Chow WH, Abnet CC. Urinary prostaglandin E2 metabolite and gastric cancer risk in the Shanghai women's health study. *Cancer Epidemiol Biomarkers Prev*. 2009;18(11):3075-8.
- Dunn BE, Cohen H, Blaser MJ. *Helicobacter pylori*. *Clin Microbiol Rev*. 1997;10(4):720-41.
- Ernst PB, Pappo J. T-cell-mediated mucosal immunity in the absence of antibody: lessons from *Helicobacter pylori* infection. *Acta Odontol Scand*. 2001;59(4):216-21.
- Erzin Y, Koksál V, Altun S, Dobrucali A, Aslan M, Erdamar S, Goksel S, Dirican A, Kocazeybek B. Role of host interleukin 1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in clinical outcomes in *Helicobacter pylori*-positive Turkish patients with dyspepsia. *J Gastroenterol*. 2008;43(9):705-10.
- Feng Y, Zhang J, Dai L, Zhang J, Wang P, Zang J, Li Y, Wang K. Inflammatory cytokine gene polymorphisms in gastric cancer cases' and controls' family members from Chinese areas at high cancer prevalence. *Cancer Lett*. 2008;270(2):250-9.
- Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn LJ, Carneiro F, Sobrinho-Simões M. *Helicobacter pylori* and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. *J Natl Cancer Inst*. 2002;94(22):1680-7.
- Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M; Japan Gast Study Group. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. *Lancet* 2008; 372(9636):392-7.
- Futagami S, Tatsuguchi A, Hiratsuka T, Shindo T, Horie A, Hamamoto T, Ueki N, Kusunoki M, Miyake K, Gudis K, Tsukui T, Sakamoto C. Monocyte chemoattractant protein 1 and CD40 ligation have a synergistic effect on vascular endothelial growth factor production through cyclooxygenase 2 upregulation in gastric cancer. *J Gastroenterol*. 2008;43(3):216-24.

- Galamb O, Györffy B, Sipos F, Dinya E, Krenács T, Berczi L, Szöke D, Spisák S, Solymosi N, Németh AM, Juhász M, Molnár B, Tulassay Z. *Helicobacter pylori* and antrum erosion-specific gene expression patterns: the discriminative role of CXCL13 and VCAM1 transcripts. *Helicobacter*. 2008;13(2):112-26.
- Gao L, Weck MN, Nieters A, Brenner H. Inverse association between a pro-inflammatory genetic profile and *Helicobacter pylori* seropositivity among patients with chronic atrophic gastritis: enhanced elimination of the infection during disease progression? *Eur J Cancer*. 2009;45(16):2860-6.
- Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI. Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. *BMC Cancer*. 2007;7:70.
- Garza-González E, Hold G, Pérez-Pérez GI, Bosques-Padilla FJ, Tijerina-Menchaca R, Maldonado-Garza HJ, el-Omar E. [Role of polymorphism of certain cytokines in gastric cancer in Mexico. Preliminary results] *Rev Gastroenterol Mex*. 2003;68(2):107-12.
- Gatti LL, Burbano RR, Zambaldi-Tunes M, de-Lábio RW, de Assumpção PP, de Arruda Cardoso-Smith M, Marques-Payão SL. Interleukin-6 polymorphisms, *Helicobacter pylori* infection in adult Brazilian patients with chronic gastritis and gastric adenocarcinoma. *Arch Med Res*. 2007;38(5):551-5.
- Gebert B, Fischer W, Haas R. The *Helicobacter pylori* vacuolating cytotoxin: from cellular vacuolation to immunosuppressive activities. *Rev Physiol Biochem Pharmacol*. 2004;152:205-20.
- Gehmert S, Velapatiño B, Herrera P, Balqui J, Santivañez L, Cok J, Vargas G, Combe J, Passaro DJ, Wen S, Meyer F, Berg DE, Gilman RH. Interleukin-1 beta single-nucleotide polymorphism's C allele is associated with elevated risk of gastric cancer in *Helicobacter pylori*-infected Peruvians. *Am J Trop Med Hyg*. 2009;81(5):804-10.
- Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, Miehlke S, Classen M, Prinz C. Clinical relevance of the *Helicobacter pylori* gene for blood-group antigen-binding adhesin. *Proc Natl Acad Sci USA*. 1999; 96(22):12778-83.
- Glas J, Török HP, Schneider A, Brünnler G, Kopp R, Albert ED, Stolte M, Folwaczny C. Allele 2 of the interleukin-1 receptor antagonist gene is associated with early gastric cancer. *J Clin Oncol*. 2004;22(23):4746-52.
- González CA, Sala N, Capellá G. Genetic susceptibility and gastric cancer risk. *Int J Cancer*. 2002;100(3):249-60.
- Goto Y, Ando T, Naito M, Goto H, Hamajima N. Inducible nitric oxide synthase polymorphism is associated with the increased risk of differentiated gastric cancer in a Japanese population. *World J Gastroenterol*. 2006;12(39):6361-5.
- Grebowska A, Moran AP, Matusiak A, Bak-Romaniszyn L, Czkwianianc E, Rechciński T, Walencka M, Płaneta-Małecka I, Rudnicka W, Chmiela M. Anti-phagocytic activity of *Helicobacter pylori* lipopolysaccharide (LPS)--possible modulation of the innate immune response to these bacteria. *Pol J Microbiol*. 2008;57(3):185-92.
- Guo T, Qian JM, Zhang JZ, Li XB, Zhao YQ. [Effects of *Helicobacter pylori* and *Helicobacter pylori*-related cytokines on apoptosis of gastric epithelial cells and mechanisms thereof] *Zhonghua Yi Xue Za Zhi*. 2006;86(38):2670-3.

- Hahm KB, Lim HY, Sohn S, Kwon HJ, Lee KM, Lee JS, Surh YJ, Kim YB, Joo HJ, Kim WS, Cho SW. *In vitro* evidence of the role of COX-2 in attenuating gastric inflammation and promoting gastric carcinogenesis. *J Environ Pathol Toxicol Oncol.* 2002;21(2):165-76.
- Hamajima N. Persistent *Helicobacter pylori* infection and genetic polymorphisms of the host. *Nagoya J Med Sci.* 2003;66(3-4):103-17.
- Hennig EE, Mernaugh R, Edl J, Cao P, Cover TL. Heterogeneity among *Helicobacter pylori* strains in expression of the outer membrane protein BabA. *Infect Immun* 2004; 72(6): 3429-35.
- Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M. SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science* 2002;295(5555):683-6.
- Höcker M, Hohenberger P. *Helicobacter pylori* virulence factors--one part of a big picture. *Lancet* 2003; 362 (9391):1231-3.
- Hou L, El-Omar EM, Chen J, Grillo P, Rabkin CS, Baccarelli A, Yeager M, Chanock SJ, Zatonski W, Sobin LH, Lissowska J, Fraumeni JF Jr, Chow WH. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. *Carcinogenesis.* 2007;28(1):118-23.
- Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. *Gastroenterology* 2003;125(6):1636-44.
- Huang L, Zhang KL, Li H, Chen XY, Kong QY, Sun Y, Gao X, Guan HW, Liu J. Infrequent COX-2 expression due to promoter hypermethylation in gastric cancers in Dalian, China. *Hum Pathol.* 2006;37(12):1557-67.
- Hussain MA, Naveed SA, Sechi LA, Ranjan S, Alvi A, Ahmed I, Ranjan A, Mukhopadhyay S, Ahmed N. Isocitrate dehydrogenase of *Helicobacter pylori* potentially induces humoral immune response in subjects with peptic ulcer disease and gastritis. *PLoS One.* 2008;3(1):e1481.
- Hynes SO, Keenan JL, Ferris JA, Annuk H, Moran AP. Lewis epitopes on outer membrane vesicles of relevance to *Helicobacter pylori* pathogenesis. *Helicobacter.* 2005;10(2):146-56.
- Ierardi E, Di Leo A, Barone M, Marangi S, Burattini O, Panarese A, Margiotta M, Francavilla R, Panella C, Francavilla A, Cuomo R. Tumor necrosis factor alpha and apoptosis in *Helicobacter pylori* related progressive gastric damage: a possible mechanism of immune system involvement in epithelial turnover regulation. *Immunopharmacol Immunotoxicol.* 2003;25(2):203-11.
- Inoue K, Shiota S, Yamada K, Gotoh K, Suganuma M, Fujioka T, Ahmed K, Iha H, Nishizono A. Evaluation of a new tumor necrosis factor-alpha-inducing membrane protein of *Helicobacter pylori* as a prophylactic vaccine antigen. *Helicobacter.* 2009;14(5):135-43.
- International Agency for Research on Cancer. Cancer incidence in five continents. *IARC Sci Publ* 2002;VIII:1-781.
- International Agency for Research on Cancer. Infection with *Helicobacter pylori*. In: *IARC monographs on the evaluation of carcinogenic risks to humans. Schistosomes, liver flukes and Helicobacter pylori.* Lyon: IARC,1994; 61:177-244.

- Jackson CB, Judd LM, Menheniott TR, Kronborg I, Dow C, Yeomans ND, Boussioutas A, Robb L, Giraud AS. Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. *J Pathol.* 2007;213(2):140-51.
- Jang TJ. The number of Foxp3-positive regulatory T cells is increased in *Helicobacter pylori* gastritis and gastric cancer. *Pathol Res Pract.* 2010;206(1):34-8.
- Jorge YC, Duarte MC, Silva AE. Gastric cancer is associated with NOS2 -954G/C polymorphism and environmental factors in a Brazilian population. *BMC Gastroenterol.* 2010;10:64.
- Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, Tanaka S, Ohmoto Y, Chayama K. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. *Anticancer Res.* 2005;25(2A):709-13.
- Kamali-Sarvestani E, Bazargani A, Masoudian M, Lankarani K, Taghavi AR, Saberifiroozi M. Association of *H. pylori* cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases. *World J Gastroenterol.* 2006;12(32):5205-10.
- Kandulski A, Malfertheiner P, Wex T. Role of regulatory T-cells in *H. pylori*-induced gastritis and gastric cancer. *Anticancer Res.* 2010;30(4):1093-103.
- Kang JM, Kim N, Lee DH, Park JH, Lee MK, Kim JS, Jung HC, Song IS. The effects of genetic polymorphisms of IL-6, IL-8, and IL-10 on *Helicobacter pylori*-induced gastroduodenal diseases in Korea. *J Clin Gastroenterol.* 2009;43(5):420-8.
- Kassai K, Yoshikawa T, Yoshida N, Hashiramoto A, Kondo M, Murase H. *Helicobacter pylori* water extract induces interleukin-8 production by gastric epithelial cells. *Dig Dis Sci.* 1999;44(2):237-42.
- Katayama Y, Takahashi M, Kuwayama H. *Helicobacter pylori* causes runx3 gene methylation and its loss of expression in gastric epithelial cells, which is mediated by nitric oxide produced by macrophages. *Biochem Biophys Res Commun.* 2009;388(3):496-500.
- Kato I, van Doorn LJ, Canzian F, Plummer M, Franceschi S, Vivas J, Lopez G, Lu Y, Gioia-Patricola L, Severson RK, Schwartz AG, Muñoz N. Host-bacterial interaction in the development of gastric precancerous lesions in a high risk population for gastric cancer in Venezuela. *Int J Cancer.* 2006;119(7):1666-71.
- Kato S, Onda M, Yamada S, Matsuda N, Tokunaga A, Matsukura N. Association of the interleukin-1 beta genetic polymorphism and gastric cancer risk in Japanese. *J Gastroenterol.* 2001;36(10):696-9.
- Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, Hiraide H, Mochizuki H. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. *Cancer.* 2001;92(8):2050-5.
- Keep S, Borlace G, Butler R, Brooks D. Role of immune serum in the killing of *Helicobacter pylori* by macrophages. *Helicobacter.* 2010;15(3):177-83.
- Kidd M, Peek RM, Lastovica AJ, Israel DA, Kummer AF, Louw JA. Analysis of iceA genotypes in South African *Helicobacter pylori* strains and relationship to clinically significant disease. *Gut.* 2001;49(5):629-35.
- Kim N, Park YS, Cho SI, Lee HS, Choe G, Kim IW, Won YD, Park JH, Kim JS, Jung HC, Song IS. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. *Helicobacter.* 2008;13(4):245-55.

- Klaamas K, Held M, Wadström T, Lipping A, Kurtenkov O. IgG immune response to *Helicobacter pylori* antigens in patients with gastric cancer as defined by ELISA and immunoblotting. *Int J Cancer*. 1996;67(1):1-5.
- Klaamas K, Kurtenkov O, Rittenhouse-Olson K, Brjalin V, Miljukhina L, Shljapnikova L, Engstrand L. Expression of tumor-associated Thomsen-Friedenreich antigen (T Ag) in *Helicobacter pylori* and modulation of T Ag specific immune response in infected individuals. *Immunol Invest*. 2002;31(3-4):191-204.
- Klaamas K, Kurtenkov O, von Mensdorff-Pouilly S, Shljapnikova L, Miljukhina L, Brjalin V, Lipping A. Impact of *Helicobacter pylori* infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer. *Immunol Invest*. 2007;36(4):371-86.
- Ko KP, Park SK, Cho LY, Gwack J, Yang JJ, Shin A, Kim CS, Kim Y, Kang D, Chang SH, Shin HR, Yoo KY. Soybean product intake modifies the association between interleukin-10 genetic polymorphisms and gastric cancer risk. *J Nutr*. 2009;139(5):1008-12.
- Komoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, Sumii K, Kajiyama G, Talley NJ. *Helicobacter pylori* infection and gastric neoplasia: correlations with histological gastritis and tumor histology. *Am J Gastroenterol*. 1998;93(8):1271-6.
- Konturek PC, Kania J, Kukharsky V, Ocker S, Hahn EG, Konturek SJ. Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. *J Physiol Pharmacol*. 2003;54(1):17-32.
- Konturek PC, Konturek SJ, Brzozowski T. *Helicobacter pylori* infection in gastric cancerogenesis. *J Physiol Pharmacol*. 2009;60(3):3-21.
- Konturek PC, Konturek SJ, Sulekova Z, Meixner H, Bielanski W, Starzynska T, Karczewska E, Marlicz K, Stachura J, Hahn EG. Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. *Aliment Pharmacol Ther*. 2001;15(7):989-99.
- Konturek SJ, Starzynska T, Konturek PC, Karczewska E, Marlicz K, Lawniczak M, Jaroszewicz-Heigelman H, Bielanski W, Hartwich A, Ziemniak A, Hahn EG. *Helicobacter pylori* and CagA status, serum gastrin, interleukin-8 and gastric acid secretion in gastric cancer. *Scand J Gastroenterol*. 2002;37(8):891-8.
- Kumar S, Kumar A, Dixit VK. Evidences showing association of interleukin-1B polymorphisms with increased risk of gastric cancer in an Indian population. *Biochem Biophys Res Commun*. 2009;387(3):456-60.
- Kurtenkov O, Klaamas K, Sergeev B, Chuzmarov V, Miljukhina L, Shljapnikova L. Better survival of *Helicobacter pylori* infected patients with early gastric cancer is related to a higher level of Thomsen-Friedenreich antigen-specific antibodies. *Immunol Invest*. 2003;32(1-2):83-93.
- Lamarque D, Tran Van Nhieu J, Breban M. [What are the gastric modifications induced by acute and chronic *Helicobacter pylori* infection?] *Gastroenterol Clin Biol*. 2003;27(3 Pt 2):391-400.
- Lee IO, Kim JH, Choi YJ, Pillinger MH, Kim SY, Blaser MJ, Lee YC. *Helicobacter pylori* CagA phosphorylation status determines the gp130-activated SHP2/ERK and JAK/STAT signal transduction pathways in gastric epithelial cells. *J Biol Chem*. 2010;285(21):16042-50.

- Lee KA, Ki CS, Kim HJ, Sohn KM, Kim JW, Kang WK, Rhee JC, Song SY, Sohn TS. Novel interleukin 1beta polymorphism increased the risk of gastric cancer in a Korean population. *J Gastroenterol*. 2004;39(5):429-33.
- Lee WP, Tai DI, Lan KH, Li AF, Hsu HC, Lin EJ, Lin YP, Sheu ML, Li CP, Chang FY, Chao Y, Yen SH, Lee SD. The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. *Clin Cancer Res*. 2005;11(18):6431-41.
- Leung WK, To KF, Go MY, Chan KK, Chan FK, Ng EK, Chung SC, Sung JJ. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. *Int J Oncol*. 2003;23(5):1317-22.
- Lewis ND, Asim M, Barry DP, Singh K, de Sablet T, Boucher JL, Gobert AP, Chaturvedi R, Wilson KT. Arginase II restricts host defense to *Helicobacter pylori* by attenuating inducible nitric oxide synthase translation in macrophages. *J Immunol*. 2010;184(5):2572-82.
- Li C, Xia B, Yang Y, Li J, Xia HH. TNF gene polymorphisms and *Helicobacter pylori* infection in gastric carcinogenesis in Chinese population. *Am J Gastroenterol*. 2005;100(2):290-4.
- Li C, Xia HH, Xie W, Hu Z, Ye M, Li J, Cheng H, Zhang X, Xia B. Association between interleukin-1 gene polymorphisms and *Helicobacter pylori* infection in gastric carcinogenesis in a Chinese population. *J Gastroenterol Hepatol*. 2007;22(2):234-9.
- Li Q, Liu N, Shen B, Zhou L, Wang Y, Wang Y, Sun J, Fan Z, Liu RH. *Helicobacter pylori* enhances cyclooxygenase 2 expression via p38MAPK/ATF-2 signalling pathway in MKN45 cells. *Cancer Lett*. 2009;278(1):97-103.
- Lin JT, Wang JT, Wang TH, Wu MS, Chen CJ. *Helicobacter pylori* infection in early and advanced gastric adenocarcinoma: a seroprevalence study in 143 Taiwanese patients. *Hepatogastroenterology*. 1993;40(6):596-9.
- Lu W, Pan K, Zhang L, Lin D, Miao X, You W. Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer in a Chinese population. *Carcinogenesis*. 2005;26(3):631-6.
- Lundin BS, Enarsson K, Kindlund B, Lundgren A, Johnsson E, Quiding-Järbrink M, Svennerholm AM. The local and systemic T-cell response to *Helicobacter pylori* in gastric cancer patients is characterised by production of interleukin-10. *Clin Immunol*. 2007;125(2):205-13.
- Manojlovic N, Babic D, Filipovic-Ljeshovic I, Pilcevic D. Anti *Helicobacter pylori* IgG and IgA response in patients with gastric cancer and chronic gastritis. *Hepatogastroenterology*. 2008;55(82-83):807-13.
- Manojlovic N, Nikolic L, Pilcevic D, Josifovski J, Babic D. Systemic humoral anti-*Helicobacter pylori* immune response in patients with gastric malignancies and benign gastroduodenal disease. *Hepatogastroenterology*. 2004;51(55):282-4.
- Marotti B, Rocco A, De Colibus P, Compare D, de Nucci G, Staibano S, Tatangelo F, Romano M, Nardone G. Interleukin-13 mucosal production in *Helicobacter pylori*-related gastric diseases. *Dig Liver Dis*. 2008;40(4):240-7.
- Marrelli D, Pedrazzani C, Berardi A, Corso G, Neri A, Garosi L, Vindigni C, Santucci A, Figura N, Roviello F. Negative *Helicobacter pylori* status is associated with poor prognosis in patients with gastric cancer. *Cancer* 2009;115(10):2071-80.

- Matysiak-Budnik T & Mégraud F. *Helicobacter pylori* infection and gastric cancer. *Eur J Cancer* 2006; 42: 708-16.
- Mbulaiteye SM, Gold BD, Pfeiffer RM, Brubaker GR, Shao J, Biggar RJ, Hisada M. *H. pylori*-infection and antibody immune response in a rural Tanzanian population. *Infect Agent Cancer*. 2006; 1:3.
- McGee DJ, Mobley HL. Pathogenesis of *Helicobacter pylori* infection. *Curr Opin Gastroenterol*. 2000;16(1):24-31.
- McNamara D, El-Omar E. *Helicobacter pylori* infection and the pathogenesis of gastric cancer: a paradigm for host-bacterial interactions. *Dig Liver Dis*. 2008;40(7):504-9.
- Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M, Stolte M, Jauch KW, Hatz RA. *Helicobacter pylori* as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. *Lancet Oncol* 2006; 7(3): 211-22.
- Mimuro H, Suzuki T, Tanaka J, Asahi M, Haas R, Sasakawa C. Grb2 is a key mediator of *Helicobacter pylori* CagA protein activities. *Mol Cell*. 2002; 10(4):745-55.
- Mollenhauer-Rektorschek M, Hanauer G, Sachs G, Melchers K. Expression of UreI is required for intragastric transit and colonization of gerbil gastric mucosa by *Helicobacter pylori*. *Res Microbiol*. 2002;153(10):659-66.
- Moran AP. The role of endotoxin in infection: *Helicobacter pylori* and *Campylobacter jejuni*. *Subcell Biochem*. 2010;53:209-40.
- Moran, AP. The role of lipopolysaccharide in *Helicobacter pylori* pathogenesis. *Aliment. Pharmacol. Ther*. 1996;10 (suppl. 1), 39-50.
- Morgan DR, Dominguez RL, Keku TO, Heidt PE, Martin CF, Galanko JA, Omofoye OA, Sandler RS. Gastric cancer and the high combination prevalence of host cytokine genotypes and *Helicobacter pylori* in Honduras. *Clin Gastroenterol Hepatol*. 2006;4(9):1103-11.
- Muñoz L, Camorlinga M, Hernández R, Giono S, Ramón G, Muñoz O, Torres J. Immune and proliferative cellular responses to *Helicobacter pylori* infection in the gastric mucosa of Mexican children. *Helicobacter*. 2007;12(3):224-30.
- Murakami K, Kodama M, Sato R, Okimoto T, Watanabe K, Fujioka T. *Helicobacter pylori* eradication and associated changes in the gastric mucosa. *Expert Rev Anti Infect Ther* 2005; 3(5): 757-64.
- Nilsson C, Skoglund A, Moran AP, Annuk H, Engstrand L, Normark S. An enzymatic ruler modulates Lewis antigen glycosylation of *Helicobacter pylori* LPS during persistent infection. *Proc Natl Acad Sci USA*. 2006;103(8):2863-8.
- Obonyo M, Sabet M, Cole SP, Ebmeyer J, Uematsu S, Akira S, Guiney DG. Deficiencies of myeloid differentiation factor 88, Toll-like receptor 2 (TLR2), or TLR4 produce specific defects in macrophage cytokine secretion induced by *Helicobacter pylori*. *Infect Immun*. 2007;75(5):2408-14.
- Odenbreit S. Adherence properties of *Helicobacter pylori*: impact on pathogenesis and adaptation to the host. *Int J Med Microbiol*. 2005;295(5):317-24
- Ohyauchi M, Imatani A, Yonechi M, Asano N, Miura A, Iijima K, Koike T, Sekine H, Ohara S, Shimosegawa T. The polymorphism interleukin 8 -251 A/T influences the susceptibility of *Helicobacter pylori* related gastric diseases in the Japanese population. *Gut*. 2005;54(3):330-5.
- Oliveira AG, Santos A, Guerra JB, Rocha GA, Rocha AM, Oliveira CA, Cabral MM, Nogueira AM, Queiroz DM. babA2- and cagA-positive *Helicobacter pylori* strains are

- associated with duodenal ulcer and gastric carcinoma in Brazil. *J Clin Microbiol.* 2003;41(8):3964-6.
- Oliveira MJ, Costa AC, Costa AM, Henriques L, Suriano G, Atherton JC, Machado JC, Carneiro F, Seruca R, Mareel M, Leroy A, Figueiredo C. *Helicobacter pylori* induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent manner. *J Biol Chem.* 2006;281(46):34888-96.
- Palli D, Saieva C, Luzzi I, Masala G, Topa S, Sera F, Gemma S, Zanna I, D'Errico M, Zini E, Guidotti S, Valeri A, Fabbrucci P, Moretti R, Testai E, del Giudice G, Ottini L, Matullo G, Dogliotti E, Gomez-Miguel MJ. Interleukin-1 gene polymorphisms and gastric cancer risk in a high-risk Italian population. *Am J Gastroenterol.* 2005;100(9):1941-8.
- Park ES, Do IG, Park CK, Kang WK, Noh JH, Sohn TS, Kim S, Kim MJ, Kim KM. Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. *Clin Cancer Res.* 2009;15(1):291-8.
- Partida-Rodríguez O, Torres J, Flores-Luna L, Camorlinga M, Nieves-Ramírez M, Lazcano E, Perez-Rodríguez M. Polymorphisms in TNF and HSP-70 show a significant association with gastric cancer and duodenal ulcer. *Int J Cancer.* 2010;126(8):1861-8.
- Peek RM Jr. Pathogenesis of *Helicobacter pylori* infection. *Springer Semin Immun.* 2005; 27:197-215.
- Persson C, Engstrand L, Nyrén O, Hansson LE, Enroth H, Ekström AM, Ye W. Interleukin 1-beta gene polymorphisms and risk of gastric cancer in Sweden. *Scand J Gastroenterol.* 2009;44(3):339-45.
- Przyklenk B, Bauernfeind A, Bornschein W, Emminger G, Heilmann K, Schweighart S. The role of *Campylobacter (Helicobacter) pylori* in disorders of the gastrointestinal tract. *Infection.* 1990;18(1):3-7.
- Quiros RM, Bui CL. Multidisciplinary approach to esophageal and gastric cancer, *Surg. Clin. North Am.* 2009;89(1): 79-96 , viii.
- Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, Gerhard M, Prinz C. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during *Helicobacter pylori* infection. *Gut.* 2004;53(8):1082-9
- Rautelin HI, Oksanen AM, Karttunen RA, Seppälä KM, Virtamo JR, Aromaa AJ, Kosunen TU. Association of CagA-positive infection with *Helicobacter pylori* antibodies of IgA class. *Ann Med.* 2000;32(9):652-6.
- Rieder G, Hofmann JA, Hatz RA, Stolte M, Enders GA. Up-regulation of inducible nitric oxide synthase in *Helicobacter pylori*-associated gastritis may represent an increased risk factor to develop gastric carcinoma of the intestinal type. *Int J Med Microbiol.* 2003;293(6):403-12.
- Rossi G, Romagnoli S, Lauretti L, Pancotto L, Taccini E, Rappuoli R, Del Giudice G, Ruggiero P. *Helicobacter pylori* infection negatively influences pregnancy outcome in a mouse model. *Helicobacter.* 2004;9(2):152-7.
- Rudi J, Kolb C, Maiwald M, Zuna I, von Herbay A, Galle PR, Stremmel W. Serum antibodies against *Helicobacter pylori* proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. *Dig Dis Sci* 1997; 42(8):1652-9.


- Ruzzo A, Graziano F, Pizzagalli F, Santini D, Battistelli V, Panunzi S, Canestrari E, Catalano V, Humar B, Ficarelli R, Bearzi I, Cascinu S, Naldi N, Testa E, Magnani M. Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in *Helicobacter pylori*-negative gastric cancer of intestinal and diffuse histotype. *Ann Oncol*. 2005;16(6):887-92.
- Sakuma K, Uozaki H, Chong JM, Hironaka M, Sudo M, Ushiku T, Nagai H, Fukayama M. Cancer risk to the gastric corpus in Japanese, its correlation with interleukin-1beta gene polymorphism (+3953*T) and Epstein-Barr virus infection. *Int J Cancer*. 2005;115(1):93-7.
- Sánchez-Zauco NA, Giono-Cerezo S, Maldonado-Bernal C. [Toll-like receptors, pathogenesis and immune response to *Helicobacter pylori*]. *Salud Publica Mex*. 2010;52(5):447-54.
- Saxena A, Prasad KN, Ghoshal UC, Bhagat MR, Krishnani N, Husain N. Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern India. *World J Gastroenterol*. 2008;14(10):1498-503.
- Segal I, Ally R, Mitchell H. *Helicobacter pylori*--an African perspective. *QJM*. 2001;94(10):561-5.
- Selbach M, Moese S, Hauck CR, Meyer TF, Backert S. Src is the kinase of *Helicobacter pylori* CagA protein *in vitro* and *in vivo*. *J Biol Chem* 2002; 277(9): 6775-8.
- Seno H, Satoh K, Tsuji S, Shiratsuchi T, Harada Y, Hamajima N, Sugano K, Kawano S, Chiba T. Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: comprehensive analysis of 207 polymorphisms of 11 cytokine genes. *J Gastroenterol Hepatol*. 2007;22(5):729-37.
- Seo JH, Kim KH, Kim H. Role of proteinase-activated receptor-2 on cyclooxygenase-2 expression in *H. pylori*-infected gastric epithelial cells. *Ann N Y Acad Sci*. 2007;1096:29-36.
- Sheu SM, Sheu BS, Yang HB, Li C, Chu TC, Wu JJ. Presence of iceA1 but not cagA, cagC, cagE, cagF, cagN, cagT, or orf13 genes of *Helicobacter pylori* is associated with more severe gastric inflammation in Taiwanese. *J Formos Med Assoc*. 2002;101(1):18-23.
- Shin WG, Jang JS, Kim HS, Kim SJ, Kim KH, Jang MK, Lee JH, Kim HJ, Kim HY. Polymorphisms of interleukin-1 and interleukin-2 genes in patients with gastric cancer in Korea. *J Gastroenterol Hepatol*. 2008;23(10):1567-73.
- Shiotani A, Iishi H, Kumamoto M, Nakae Y. *Helicobacter pylori* infection and increased nitrite synthesis in the stomach. Inflammation and atrophy connections. *Dig Liver Dis*. 2004;36(5):327-32.
- Shirai K, Ohmiya N, Taguchi A, Mabuchi N, Yatsuya H, Itoh A, Hirooka Y, Niwa Y, Mori N, Goto H. Interleukin-8 gene polymorphism associated with susceptibility to non-cardia gastric carcinoma with microsatellite instability. *J Gastroenterol Hepatol*. 2006;21(7):1129-35.
- Sicinschi LA, Lopez-Carrillo L, Camargo MC, Correa P, Sierra RA, Henry RR, Chen J, Zabaleta J, Piazuelo MB, Schneider BG. Gastric cancer risk in a Mexican population: role of *Helicobacter pylori* CagA positive infection and polymorphisms in interleukin-1 and -10 genes. *Int J Cancer*. 2006;118(3):649-57.
- Snider JL, Cardelli JA. *Helicobacter pylori* induces cancer cell motility independent of the c-Met receptor. *J Carcinog*. 2009;8:7

- Sokic-Milutinovic A, Wex T, Todorovic V, Milosavljevic T, Malfertheiner P. Anti-CagA and anti-VacA antibodies in *Helicobacter pylori*-infected patients with and without peptic ulcer disease in Serbia and Montenegro. *Scand J Gastroenterol* 2004; 39(3): 222-6.
- Son HJ, Rhee JC, Park DI, Kim YH, Rhee PL, Koh KC, Paik SW, Choi KW, Kim JJ. Inducible nitric oxide synthase expression in gastroduodenal diseases infected with *Helicobacter pylori*. *Helicobacter*. 2001;6(1):37-43.
- Starzyńska T, Ferenc K, Wex T, Kähne T, Lubiński J, Lawniczak M, Marlicz K, Malfertheiner P. The association between the interleukin-1 polymorphisms and gastric cancer risk depends on the family history of gastric carcinoma in the study population. *Am J Gastroenterol*. 2006;101(2):248-54.
- Stingl K, Uhlemann EM, Schmid R, Altendorf K, Bakker EP. Energetics of *Helicobacter pylori* and its implications for the mechanism of urease-dependent acid tolerance at pH 1. *J Bacteriol*. 2002;184(11):3053-60.
- Sugimoto M, Furuta T, Shirai N, Nakamura A, Xiao F, Kajimura M, Sugimura H, Hishida A. Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. *J Gastroenterol Hepatol*. 2007;22(1):51-9.
- Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Sugimura H, Hishida A. Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. *J Gastroenterol Hepatol*. 2007;22(9):1443-9.
- Sugimoto M, Yamaoka Y, Furuta T. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. *World J Gastroenterol*. 2010;16(10):1188-200.
- Suzuki M, Mimuro H, Kiga K, Fukumatsu M, Ishijima N, Morikawa H, Nagai S, Koyasu S, Gilman RH, Kersulyte D, Berg DE, Sasakawa C. *Helicobacter pylori* CagA phosphorylation-independent function in epithelial proliferation and inflammation. *Cell Host Microbe*. 2009;5(1):23-34.
- Taguchi A, Ohmiya N, Shirai K, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. *Cancer Epidemiol Biomarkers Prev*. 2005;14(11 Pt 1):2487-93.
- Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, Fujii Y, Okubo M, Zaito Y, Ariyoshi K, Nakamura Y, Nawata R, Oka Y, Shirai M, Tanizawa Y. Molecular mimicry by *Helicobacter pylori* CagA protein may be involved in the pathogenesis of *H. pylori*-associated chronic idiopathic thrombocytopenic purpura. *Br J Haematol* 2004; 124(1): 91-6.
- Takehara H, Iwamoto J, Mizokami Y, Takahashi K, Ootubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokobe K, Ito M, Matsuoka T. Involvement of cyclooxygenase-2--prostaglandin E2 pathway in interleukin-8 production in gastric cancer cells. *Dig Dis Sci*. 2006;51(12):2188-97.
- Tanaka A, Kamada T, Yokota K, Shiotani A, Hata J, Oguma K, Haruma K. *Helicobacter pylori* heat shock protein 60 antibodies are associated with gastric cancer. *Pathol Res Pract*. 2009;205(10):690-4.
- Tatemichi M, Ogura T, Nagata H, Esumi H. Enhanced expression of inducible nitric oxide synthase in chronic gastritis with intestinal metaplasia. *J Clin Gastroenterol*. 1998;27(3):240-5.

- Tatemichi M, Sawa T, Gilibert I, Tazawa H, Katoh T, Ohshima H. Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. *Cancer Lett.* 2005;217(2):197-202.
- Taylor JM, Ziman ME, Huff JL, Moroski NM, Vajdy M, Solnick JV. *Helicobacter pylori* lipopolysaccharide promotes a Th1 type immune response in immunized mice. *Vaccine.* 2006;24(23):4987-94.
- Tiwari SK, Manoj G, Sharma V, Sivaram G, Saikant R, Bardia A, Sharma VK, Abid Z, Khan AA, Habeeb MA, Habibullah CM, Kumar BS, Nandan A. Relevance of *Helicobacter pylori* genotypes in gastric pathology and its association with plasma malondialdehyde and nitric oxide levels. *Inflammopharmacology.* 2010;18(2):59-64.
- Toller IM, Hitzler I, Sayi A, Mueller A. Prostaglandin E2 prevents *Helicobacter*-induced gastric preneoplasia and facilitates persistent infection in a mouse model. *Gastroenterology.* 2010;138(4):1455-67, 1467.e1-4.
- Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzgerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Wattney L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC. The complete genome sequence of the gastric pathogen *Helicobacter pylori*. *Nature.* 1997;388(6642):539-47.
- Torres MM, Acosta CP, Sicard DM, et al. [Genetic susceptibility and risk of gastric cancer in a human population of Cauca, Colombia] *Biomedica.* 2004;24(2):153-62.
- Tsai HF & Hsu PN. Interplay between *Helicobacter pylori* and immune cells in immune pathogenesis of gastric inflammation and mucosal pathology. *Cell Mol Immunol.* 2010;7(4):255-9.
- Tsuji S, Tsujii M, Murata H, Nishida T, Komori M, Yasumaru M, Ishii S, Sasayama Y, Kawano S, Hayashi N. *Helicobacter pylori* eradication to prevent gastric cancer: underlying molecular and cellular mechanisms. *World J Gastroenterol.* 2006;12(11):1671-80.
- Turbett GR, Høj PB, Horne R, Mee BJ. Purification and characterization of the urease enzymes of *Helicobacter* species from humans and animals. *Infect Immun.* 1992;60(12):5259-66.
- Umehara S, Higashi H, Ohnishi N, Asaka M, Hatakeyama M. Effects of *Helicobacter pylori* CagA protein on the growth and survival of B lymphocytes, the origin of MALT lymphoma. *Oncogene.* 2003;22(51):8337-42.
- van den Engel NK, Winter H, Rüttinger D, Shau I, Schiller M, Mayer B, Moudgil T, Meimarakis G, Stolte M, Jauch KW, Fox BA, Hatz RA. Characterization of immune responses in gastric cancer patients: a possible impact of *H. pylori* to polarize a tumor-specific type 1 response? *Clin Immunol.* 2006;120(3):285-96.
- Varro A, Noble PJ, Pritchard DM, Kennedy S, Hart CA, Dimaline R, Dockray GJ. *Helicobacter pylori* induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis. *Cancer Res.* 2004;64(5):1695-702.

- Vaucher C, Janvier B, Nousbaum JB, Grignon B, Pezennec L, Robaszekiewicz M, Gouerou H, Picard B, Fauchere JL. Antibody response of patients with *Helicobacter pylori*-related gastric adenocarcinoma: significance of anti-cagA antibodies. *Clin Diagn Lab Immunol* 2000; 7(3): 463-7.
- Vieth M, Stolte M. Elevated risk for gastric adenocarcinoma can be predicted from histomorphology. *World J Gastroenterol*. 2006;12(38):6109-14.
- Vivas JR, Regnault B, Michel V, Bussière FI, Avé P, Huerre M, Labigne A, D' Elios MM, Touati E. Interferon gamma-signature transcript profiling and IL-23 upregulation in response to *Helicobacter pylori* infection. *Int J Immunopathol Pharmacol*. 2008;21(3):515-26.
- Vorobjova T, Ren Z, Dunkley M, Clancy R, Maarros HI, Labotkin R, Kull K, Uibo R. Response of IgG1 and IgG2 subclasses to *Helicobacter pylori* in subjects with chronic inflammation of the gastric mucosa, atrophy and gastric cancer in a country with high *Helicobacter pylori* infection prevalence. *APMIS*. 2006;114(5):372-80.
- Walduck AK, Weber M, Wunder C, Juettner S, Stolte M, Vieth M, Wiedenmann B, Meyer TF, Naumann M, Hoecker M. Identification of novel cyclooxygenase-2-dependent genes in *Helicobacter pylori* infection *in vivo*. *Mol Cancer*. 2009;8:22.
- Wang SK, Zhu HF, He BS, Zhang ZY, Chen ZT, Wang ZZ, Wu GL. CagA+ H pylori infection is associated with polarization of T helper cell immune responses in gastric carcinogenesis. *World J Gastroenterol*. 2007;13(21):2923-31.
- Wex T, Leodolter A, Bornschein J, Kuester D, Kähne T, Kropf S, Albrecht C, Naumann M, Roessner A, Malfertheiner P. Interleukin 1 beta (IL1B) gene polymorphisms are not associated with gastric carcinogenesis in Germany. *Anticancer Res*. 2010;30(2):505-11.
- Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. *Helicobacter pylori* Eradication to Prevent Gastric Cancer in a High-Risk Region of China: A Randomized Controlled Trial. *JAMA*. 2004;291(2):187-194
- Wu MS, Lin JT, Hsu PN, Lin CY, Hsieh YT, Chiu YH, Hsueh PR, Liao KW. Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by *Helicobacter pylori* soluble proteins. *J Infect Dis*. 2007;196(9):1386-93.
- Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. *Int J Cancer*. 2003;104(5):617-23.
- Wu YY, Tsai HF, Lin WC, Hsu PI, Shun CT, Wu MS, Hsu PN. Upregulation of CCL20 and recruitment of CCR6+ gastric infiltrating lymphocytes in *Helicobacter pylori* gastritis. *Infect Immun*. 2007;75(9):4357-63.
- Xia HH, Talley NJ. Apoptosis in gastric epithelium induced by *Helicobacter pylori* infection: implications in gastric carcinogenesis. *Am J Gastroenterol*. 2001;96(1):16-26.
- Xiao H, Jiang Y, Li R, Xia B. [Association of IL-10 gene polymorphisms with gastroduodenal diseases in Hubei Han population]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. 2009;26(4):423-6.
- Xue LJ, Su QS, Yang JH, Lin Y. Autoimmune responses induced by *Helicobacter pylori* improve the prognosis of gastric carcinoma. *Med Hypotheses*. 2008;70(2):273-6.
- Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relation between cytokines and *Helicobacter pylori* in gastric cancer. *Helicobacter*. 2001;6(2):116-24.

- Yang J, Hu Z, Xu Y, Shen J, Niu J, Hu X, Guo J, Wei Q, Wang X, Shen H. Interleukin-1B gene promoter variants are associated with an increased risk of gastric cancer in a Chinese population. *Cancer Lett.* 2004;215(2):191-8.
- Yang JJ, Ko KP, Cho LY, Shin A, Gwack J, Chang SH, Shin HR, Yoo KY, Kang D, Park SK. The role of TNF genetic variants and the interaction with cigarette smoking for gastric cancer risk: a nested case-control study. *BMC Cancer.* 2009;9:238.
- Yoo EJ, Park SY, Cho NY, Kim N, Lee HS, Kim D, Kang GH. Influence of IL1B polymorphism on CpG island hypermethylation in *Helicobacter pylori*-infected gastric cancer. *Virchows Arch.* 2010;456(6):647-52.
- Zabaleta J, Camargo MC, Ritchie MD, Piazuolo MB, Sierra RA, Turner SD, Delgado A, Fonham ET, Schneider BG, Correa P, Ochoa AC. Association of haplotypes of inflammation-related genes with gastric preneoplastic lesions in African Americans and Caucasians. *Int J Cancer.* 2011;128(3):668-75.
- Zabaleta J, McGee DJ, Zea AH, Hernández CP, Rodriguez PC, Sierra RA, Correa P, Ochoa AC. *Helicobacter pylori* arginase inhibits T cell proliferation and reduces the expression of the TCR zeta-chain (CD3zeta). *J Immunol.* 2004;173(1):586-93.
- Zambon CF, Basso D, Navaglia F, Belluco C, Falda A, Fogar P, Greco E, Gallo N, Rugge M, Di Mario F, Plebani M. Pro- and anti-inflammatory cytokines gene polymorphisms and *Helicobacter pylori* infection: interactions influence outcome. *Cytokine.* 2005;29(4):141-52.
- Zhang LJ, Wang SY, Huo XH, Zhu ZL, Chu JK, Ma JC, Cui DS, Gu P, Zhao ZR, Wang MW, Yu J. Anti-*Helicobacter pylori* therapy followed by celecoxib on progression of gastric precancerous lesions. *World J Gastroenterol.* 2009;15(22):2731-8.
- Zhang XM, Miao XP, Tan W, Sun T, Guo YL, Zhao D, Lin DX. [Genetic polymorphisms in the promoter region of cyclooxygenase-2 and their association with risk of gastric cancer]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao.* 2006;28(2):119-23.
- Zhu F, Loh M, Hill J, Lee S, Koh KX, Lai KW, Salto-Tellez M, Iacopetta B, Yeoh KG, Soong R; Singapore Gastric Cancer Consortium. Genetic factors associated with intestinal metaplasia in a high risk Singapore-Chinese population: a cohort study. *BMC Gastroenterol.* 2009;9:76.
- Zhu KX, Li YM, Li X, Zhou WC, Shan Y, Liu T. Study on the association of COX-2 genetic polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu province in China. *Mol Biol Rep.* 2011;38(1):649-55.
- Zhuang X, Lin S, Zheng J, Wang L, Sun G, Li Y. The prognostic research of expression and relationship between *Helicobacter pylori* of c-met oncogene correlation with gastric mucosal proliferation. *Zhonghua Nei Ke Za Zhi.* 2001;40(6):381-4.



Gastric Carcinoma - Molecular Aspects and Current Advances

Edited by Prof. Mahmoud Lotfy

ISBN 978-953-307-412-2

Hard cover, 354 pages

Publisher InTech

Published online 15, June, 2011

Published in print edition June, 2011

Gastric cancer is one of the most common tumors worldwide. It has a heterogeneous milieu, where the genetic background, tumor immunology, oxidative stress, and microbial infections are key players in the multiple stages of tumorigenesis. These diverse factors are linked to the prognosis of the gastric cancer and the survival of gastric cancer patients. This book is appropriate for scientists and students in the field of oncology, gastroenterology, molecular biology, immunology, cell biology, biology, biochemistry, and pathology. This authoritative text carefully explains the fundamentals, providing a general overview of the principles followed by more detailed explanations of these recent topics efficiently. The topics presented herein contain the most recent knowledge in gastric cancer concerning the oncogenic signaling, genetic instability, the epigenetic aspect, molecular features and their clinical implications, miRNAs, integrin and E-cadherin, carbohydrate-associated-transferases, free radicals, immune cell responses, mucins, *Helicobacter-pylori*, neoadjuvant and adjuvant therapy, prophylactic strategy for peritoneal recurrence, and hepatic metastasis.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Li-Jun Xue, Quan-Sheng Su, Xiao-Bei Mao, Xiao-Bei Liu, Qing Lin, Chang Liu, Yong Lin, Ji-Hong Yang, Hong-Ju Yu and Xiao-Yuan Chu (2011). A Double-Edged Sword: Roles of *Helicobacter Pylori* in Gastric Carcinoma, *Gastric Carcinoma - Molecular Aspects and Current Advances*, Prof. Mahmoud Lotfy (Ed.), ISBN: 978-953-307-412-2, InTech, Available from: <http://www.intechopen.com/books/gastric-carcinoma-molecular-aspects-and-current-advances/a-double-edged-sword-roles-of-helicobacter-pylori-in-gastric-carcinoma>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](#), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen